CONFIDENTIAL   
 
 
 
 
 
 
 
 
NIDA CTN Protocol 0107  
 
Peer Intervention to Link Overdose 
Survivors to Treatment  
(PI[INVESTIGATOR_8571])  
 
 
 
 
Lead Investigator:  Kelly Barth , DO 
 
 
Sponsor: National Institute on Drug Abuse (NIDA)  
May 26, 2022  
Version 6.0 

NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
i Lead Investigator (LI):  Kelly Barth, DO  
 Southern Consortium Node  
 Department of Psychiatry and Behavioral Sciences  
Medical University of South Carolina  
  
Co-Investigators : Kathleen Brady, MD, PhD  
 Southern Consortium Node  
 Department of Psychiatry and Behavioral Sciences  
Medical University of South Carolina  
  
 Jenna McCauley, PhD  
 Southern Consortium Node  
 Department of Psychiatry and Behavioral Sciences  
Medical University of South Carolina  
  
 Louise Haynes, MSW  
 Southern Consortium Node  
 Department of Psychiatry and Behavioral Sciences  
Medical University of South Carolina  
  
 Lindsey Jennings, MD  
 Southern Consortium Node  
 Department of Emergency Medicine  
Medical University of South Carolina  
  
 Susan Sonne, PharmD  
 Southern Consortium Node  
 Department of Psychiatry and Behavioral Sciences  
Medical University of South Carolina  
  
Consultant  Richard Jones, MBA, LCAS, CCS, CCDP, CAI  
 CEO/COO, FAVOR Greenville  
  
National Project Director , Erin McClure, PhD  
 Co-Investigator  Southern Consortium Node  
 Department of Psychiatry and Behavioral Sciences  
Medical University of South Carolina  
  
Project Training Director , Timothy  Matheson, PhD  
Co-Investigator  Western States Node  
 San Francisco Department of Public Health  
  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
ii   
CCTN  Scientific Officer s: Yanpi[INVESTIGATOR_89968], PhD  
 National Institute on Drug Abuse  
  
Data and Statistics Center (DSC):  Jennifer McCormack , MS 
 DSC Principal Investigator  
 [INVESTIGATOR_268395] (CCC):  Eve Jelstrom, MBA, CRNA  
 CCC Principal Investigator  
 [INVESTIGATOR_268396]. Acceptance of this document constitutes 
agreement by [CONTACT_1955][INVESTIGATOR_268397].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326741] OF ABBREVIATIONS  ................................ ................................ ................................ ..............  1 
 STUDY SYNOPSIS  ................................ ................................ ................................ ...........................  2 
 Study Objectives  ................................ ................................ ................................ ...................  2 
 Study Design and Outcomes  ................................ ................................ ................................  2 
 Sample Size and Study Population  ................................ ................................ ......................  2 
 Treatment, Assessment, Intervention, and Duration  ................................ ............................  2 
 Safety Reporting  ................................ ................................ ................................ ...................  3 
 Analyses  ................................ ................................ ................................ ...............................  4 
 STUDY SCHEMA  ................................ ................................ ................................ .............................  5 
 Key Research Site Roles  ................................ ................................ ................................ ...... 5 
 INTRODUCTION  ................................ ................................ ................................ ...............................  6 
 Background and Significance to the Field  ................................ ................................ ............  6 
 Study Rationale  ................................ ................................ ................................ ....................  7 
 PRIMARY AIMS, OBJECTIVES, AND HYPOTHESES  ................................ ................................ ... 9 
 Overview  ................................ ................................ ................................ ...............................  9 
 Primary Aim  ................................ ................................ ................................ ........................  10 
 Secondary Aims  ................................ ................................ ................................ ..................  10 
 Exploratory Aims  ................................ ................................ ................................ .................  10 
 STUDY DESIGN  ................................ ................................ ................................ .............................  11 
 Overview of Study Design  ................................ ................................ ................................ .. 11 
 Duration of Study and Visit Schedule  ................................ ................................ .................  12 
 OUTCOME MEASURES  ................................ ................................ ................................ ................  14 
 Primary Outcome Measure  ................................ ................................ ................................ . 14 
 Hypothesis 1 (Primary Outcome Measure):  ................................ ................................ ........  14 
 Secondary Outcome Measures  ................................ ................................ ..........................  14 
 Hypothesis 2 (Secondary Outcome Measure)  ................................ ................................ .... 15 
 Other Outcome Measures  ................................ ................................ ................................ .. 17 
 Pi[INVESTIGATOR_268398]  ................................ ................................ ................................ ........  18 
 Study Timeline  ................................ ................................ ................................ ....................  19 
 STUDY POPULATION  ................................ ................................ ................................ ...................  20 
 Participant Inclusion Criteria  ................................ ................................ ...............................  20 
 Participant Exclusion Criteria  ................................ ................................ ..............................  21 
 Rationale for Inclusion/Exclusion  ................................ ................................ ........................  21 
 Strategies for Recruitment and Retention  ................................ ................................ ..........  22 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
iv 
 Recruitment provisions for modified operations due to COVID -19, other population -level 
safety concerns, or low enrollment at sites:  ................................ ................................ ....... 23 
[IP_ADDRESS]  Remote Recruitment/Enrollment  ................................ ................................ ................................ . 23 
[IP_ADDRESS]  Community Recruitment  ................................ ................................ ................................ ...............  23 
[IP_ADDRESS]  Modified Inclusion/Exclusion Criteria for Community Recruitment  ................................ .............  [ADDRESS_326742] Release Forms .......................  29 
 Eligibility Confirmation, Screening, and Baseline Assessments  ................................ ........  29 
 Randomization  ................................ ................................ ................................ ....................  29 
 Treatment/Intervention ................................ ................................ ................................ ........  29 
 30-, 90-, and 180 -day Assessments  ................................ ................................ ...................  30 
 Weekly Mobile Surveys  ................................ ................................ ................................ ...... 31 
 Follow -Up Assessment (Day 210)  ................................ ................................ ......................  31 
 Premature Withdrawal of Participants  ................................ ................................ ................  31 
 Study Halting Rules  ................................ ................................ ................................ ............  32 
 Blinding  ................................ ................................ ................................ ...............................  32 
 Participant Reimbursement  ................................ ................................ ................................  32 
 STUDY ASSESSMENTS  ................................ ................................ ................................ ................  34 
 Overview  ................................ ................................ ................................ .............................  34 
 Table 1: Table of Assessments/Forms  ................................ ................................ ...............  34 
 Screening Measures  ................................ ................................ ................................ ...........  36 
 Screening Enrollment  ................................ ................................ ................................ ..........  36 
 Prisoner Status Assessment  ................................ ................................ ...............................  36 
 Demographics Form  ................................ ................................ ................................ ............  36 
 Alcohol and Substance Use History (PhenX Tier 1)  ................................ ...........................  36 
 Informed Consent and Research Authorization  ................................ ................................ .. 37 
 Participant Eligibility Summary and Randomization  ................................ ............................  37 
 Screening Exit Survey  ................................ ................................ ................................ .........  37 
 General Measures  ................................ ................................ ................................ ..............  37 
 Patient Health Questionnaire (PHQ -9) ................................ ................................ ................  37 
 Visit Documentation  ................................ ................................ ................................ ............  37 
 Locator Information Form  ................................ ................................ ................................ .... 38 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
v 
 MOUD Current Status  ................................ ................................ ................................ .........  38 
 Timeline Follow -Back (TLFB)  ................................ ................................ ..............................  [ADDRESS_326743] for Substance Use  ................................ ................................ ...................  38 
 ED MOUD  ................................ ................................ ................................ ...........................  38 
 End of Treatment Form  ................................ ................................ ................................ ....... 39 
 Quality of Life (Qol)  ................................ ................................ ................................ .............  39 
 Crime and Criminal Justice  ................................ ................................ ................................ . 39 
 Treatment/Study Satisfaction Form  ................................ ................................ .....................  [ADDRESS_326744] (ORBC; Primary Outcome)  ................................ ..........  39 
 Steps Achieved Along SUD Cascade of Care Assessment Battery (Secondary Outcome)
 ................................ ................................ ................................ ................................ ............  [ADDRESS_326745]  ................................ ................................ ................................ ... 40 
 Step 2 -7 Assessment Form  ................................ ................................ ................................ . 40 
 MOUD Confirmation Form  ................................ ................................ ................................ .. 40 
 Assessment of Recovery Capi[INVESTIGATOR_307] (ARC) Scale [34]  ................................ ............................  41 
 Exploratory Outcomes  ................................ ................................ ................................ ........  41 
 Overdose Information [41]  ................................ ................................ ................................ ... [ADDRESS_326746] for Nicotine Dependence [42]  ................................ ................................ .. 43 
 Cannabis Use Assessment  ................................ ................................ ................................ . 43 
 Weekly Mobile Surveys  ................................ ................................ ................................ ...... 43 
 PI[INVESTIGATOR_268399]  ................................ ................................ ................................ ..............  43 
 PI[INVESTIGATOR_268400]  ................................ ................................ ........................  43 
 Supervisor Log  ................................ ................................ ................................ ....................  43 
 Study Site Surveys  ................................ ................................ ................................ .............  43 
 PI[INVESTIGATOR_268401]  ................................ ................................ .............................  44 
 TRAINING REQUIREMENTS  ................................ ................................ ................................ .........  45 
 Overall  ................................ ................................ ................................ ................................  45 
 Training, Supervision, and Fidelity Monitoring Procedures for Study Interventions  ...........  45 
 Selection of Interventionists/Care Facilitators  ................................ ................................ ..... 45 
 Selection of Expert Trainers  ................................ ................................ ................................  46 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
vi 
 Training of Certified Peer Support Specialists  ................................ ................................ .... 46 
 Treatment Fidelity (Evaluation of Treatment Integrity)  ................................ ........................  47 
 CONCOMITANT THERAPY/INTERVENTION  ................................ ................................ ...............  48 
 General  ................................ ................................ ................................ ...............................  48 
 STATISTICAL DESIGN AND ANALYSES  ................................ ................................ ....................  49 
 General Design  ................................ ................................ ................................ ...................  49 
 Study Hypothesis and Objectives  ................................ ................................ .......................  49 
 Randomization and Factors for Stratification  ................................ ................................ ...... 50 
 Rationale for Sample Size and Statistical Power  ................................ ...............................  50 
 Table 2: Power Results  ................................ ................................ ................................ ...... [ADDRESS_326747] (HIPAA)  ................................ ..................  63 
 Investigator Assurances  ................................ ................................ ................................ ..... 63 
 Financial Disclosure/Conflict of Interest  ................................ ................................ ..............  63 
 Clinical Monitoring  ................................ ................................ ................................ ..............  63 
 Inclusion of Women and Minorities  ................................ ................................ .....................  64 
 Prisoner Certification  ................................ ................................ ................................ ..........  64 
 Regulatory Files  ................................ ................................ ................................ ..................  65 
 Records Retention and Requirements  ................................ ................................ ...............  65 
 Reporting to Sponsor  ................................ ................................ ................................ ..........  65 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326748] (DSMB)  ................................ ................................ ........  68 
 Safety Monitor/Medical Monitor  ................................ ................................ ...........................  68 
 Safety Events  ................................ ................................ ................................ ......................  68 
 DATA MANAGEMENT  ................................ ................................ ................................ ...................  69 
 Design and Development  ................................ ................................ ................................ ... 69 
 Site Responsibilities ................................ ................................ ................................ ............  69 
 Data Center Responsibilities  ................................ ................................ ..............................  69 
 Data Collection  ................................ ................................ ................................ ...................  69 
 Data Acquisition and Entry  ................................ ................................ ................................ . 70 
 Data Editing  ................................ ................................ ................................ ........................  70 
 Data Transfer/Lock  ................................ ................................ ................................ .............  70 
 Data Training  ................................ ................................ ................................ ......................  70 
 Data Quality Assurance  ................................ ................................ ................................ ...... 70 
 DATA SHARING, PUBLIC ACCESS, AND PUBLICATIONS  ................................ .......................  71 
 PROTOCOL SIGNATURE [CONTACT_1783]  ................................ ................................ ................................ .. 72 
 REFERENCES  ................................ ................................ ................................ ................................  73 
 APPENDIX A: DATA AND SAFETY MONITORING PLAN (DSMP)  ................................ .............  76 
 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326749] Deviation  
SDS Saliva Drug Screen  
SUD  Substance Use Disorder  
TAU Treatment As Usual  
TLFB  Timeline Follow -Back  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
2 
 STUDY SYNOPSIS  
 Study Objectives  
The primary objective of this study is to advance understanding and improve outcomes for 
individuals who present to an Emergency Department (ED) after surviving a non -fatal overdose 
involving opi[INVESTIGATOR_2438] (NFOO). To achieve this objective, the study  will evaluate the preliminary 
effectiveness of a specialized , enhanced peer recovery intervention tailored for NFOO survivors, 
called Peer Intervention to Link Overdose Survivors to Treatment (PI[INVESTIGATOR_8571]), on self -reported 
overdose risk behaviors for individuals who present to the ED after a NFOO. The PI[INVESTIGATOR_268402] (TAU) in the ED setting.  
The secondary objectives  of the study are to: 1) evaluate the number of steps achieved along a 
modified Substance Use Disorder (SUD) Cascade of Care for individuals randomized to PI[INVESTIGATOR_268403], and 2) to assess whether NFOO survivors within an ED setting are willing to engage with 
overdose peer support using the PI[INVESTIGATOR_268404] (feasibility).  
 Study Design and Outcomes  
This is a multi -site, prospective, randomized, controlled pi[INVESTIGATOR_268405] (TAU) on the frequency of self -reported overdose risk 
behaviors for those who survive a NFOO and present to the ED.  
The first aim of this study is to test the hypothesis that PI[INVESTIGATOR_268406] a reduced  frequency of 
self-reported overdose risk behaviors among NFOO survivors at 180 days (end of treatment) 
compared to TAU (primary outcome measure) . 
The secondary aims of the study are to:  1) evaluate the number of steps achieved along a 
modified SUD Cascade of Care among individuals with a recent NFOO , and 2) assess whether 
NFOO survivors within an ED setting are willing to engage in study procedures and with peer 
support specialists, measured by (a) the number of potentially eligible patients approached 
compared with the number willing to be enrolled, and (b) the length of engagement and enrollment 
in PI[INVESTIGATOR_268407].  
 Sample Size and Study Population  
A total of approximately 150 eligible patients  (ages 18+) who have been identified as having a  
recent  NFOO in the ED will be randomized ( approximately 50 per each of 3 sites) in a 1:1 ratio to 
either TAU or PI[INVESTIGATOR_268408] 12 months of recruitment.  
 Treatment , Assessment , Intervention , and Duration   
Study staff  will identify  eligible patients in the ED by [CONTACT_268577], screening, and/or 
through ED staff identification and referral. All participants will be screened for eligibility, 
consented and will then complete baseline  study procedures.  After screening and consent, 
participants will be randomized to PI[INVESTIGATOR_268409] . 
Participants randomized to TAU will continue with routine clinical treatment in the ED. All EDs in 
this study will have peer support specialists (referred to as Certified Peer Support Specialist 
[CPSS] in South Carolina but  may have other official titles in other states) operationalized in the 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
3 ED for Screening, Brief Intervention, Referral to Treatment ( SBIRT )-like interventions for patients 
presenting with substance  use disorders  or substance -related issues . Therefore,  aside from 
standard ED medical treatment, TAU participants may also interact with TAU peer specialists for 
an SBIRT -like intervention (depending on staffing and availability). All TAU participants will be 
provided with referral and community resource info rmation, consisting of at least (1) a handout 
providing names, locations, and telephone numbers of addiction treatment services in the area; 
(2) telephone access to call a clinician or facility of their choice, which  will be informed by [CONTACT_268578] ; and (3) information about receiving naloxone per state 
regulations and community resources. TAU participants will also meet separately with the 
research staff  to complete study assessments , including a 210-day (7-month) follow -up visit after 
the 180-day (6-month) intervention window has closed .  
Those randomized to the PI[INVESTIGATOR_268410] (including the TAU peer  as available ) and meet with PI[INVESTIGATOR_268411] – a peer with 
specialized training in overdose survivor  engagement . The PI[INVESTIGATOR_268412] , and  PI[INVESTIGATOR_268413] 180 days (6 months) . Contact [CONTACT_118735][INVESTIGATOR_268414]-person, virtually  (vide o, telephone and/or text) , or a combination of both approaches. 
Those randomized to PI[INVESTIGATOR_268415], including a 7-month follow -up visit after the 6-month intervention window has 
closed (210-day follow -up study visit).  
Given potential access restrictions to EDs due to the COVID -[ADDRESS_326750]-index visit overdose s, suicidal ideation, 
Emergency Department (ED) visit s, and hospi[INVESTIGATOR_059] s will be solicited during the 30 -, 90-, 180-, 
and 210 -day visits (or in -between visits if reported spontaneously). Reporting timeframes for these 
targeted Safety Events  will follow regulatory requirements. While active suicidal ideation at the 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
4 screening /baseline  visit is considered an exclusion criterion , participant suicidal ideation occurring 
after enrollment will be addressed in accordance with Section 11.7.1 . 
For the purpose s of this protocol , the following events do not require reporting in the data system:  
• Pregnancy  
• Admission for detoxification  
• Elective hospi[INVESTIGATOR_268416], frequency of self -reported overdose risk behaviors, will be compared 
between TAU and PI[INVESTIGATOR_268417] [ADDRESS_326751] is measured by a rate ratio (RR) from the model, 
interpreted as the ratio of the mean frequency of self -reported overdos e risk behaviors for PI[INVESTIGATOR_268418], conditional on all over covariates being equal (including baseline frequency), at 180  days. 
A RR value of less than 1 indicates a lower mean frequency for PI[INVESTIGATOR_268419].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
5 
 STUDY SCHEMA  
 
Figure 1: Schema to identify  potential study participants, engage  the participant , assess interest 
in the study, screen, and enroll study participants into CTN -0107 as part of in -person ED 
procedures. This figure does not display the process of identification of patients and enrollment, 
should access to the ED be restricted. Those plans are described below.  TAU is delivered to all 
study participants, including PI[INVESTIGATOR_268420].  
 Key Research Site Roles  
Site Principal Investigator /Site Director  
PI[INVESTIGATOR_268421] ( Certified Peer Support Specialists  trained to deliver the PI[INVESTIGATOR_268422])  
PI[INVESTIGATOR_268423] /Research Assistant  

NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
6 
 INTRODUCTION  
 Background and Significance to the Field  
The alarming increase in number of overdose deaths globally [1] and in the [LOCATION_002] (US)  
specifically  over the past decade has led to a decrease in average life expectancy for the nation  
[2]. One of the greatest risk factors for overdose death is experiencing a non -fatal overdose 
involving opi[INVESTIGATOR_2438] (NFOO) in the previous year, with estimates of 5.5%  [3] to 10% [4] of individuals 
experiencing an NFOO dying within the next year. NFOO survivors most commonly die of another 
overdose (67%, average age 39 ) [3], with the highest risk period being the month following NFOO  
[5].  
With over 140,000 visits to E mergency Departments (ED s) per year for non -fatal overdoses in the 
US [4], the ED setting provides a reachable moment  for intervention in this population  [6, 7] . 
However, although successful  medical interventions have been implemented across the nation to 
broaden the initiation of medications for opi[INVESTIGATOR_2427] (MOUD) in the ED [8], which is known 
to decrease mortality for those with OUD  [9, 10] , NFOO survivors have low rates of treatment 
engagement, with only 34% engaging in substance use disorder (SUD) treatment in the year after 
NFOO [3]. 
The reasons for low engagement in SUD treatment after NFOO are multifactorial. In addition to 
low motivation for treatment in some and barriers to treatment engagement (e.g., financial and 
logistical) in individuals motivated for treatment [11], it is known that only 47% of those 
experiencing a NFOO have a known diagnosis  of SUD, with only 27% having an OUD diagnosis  
[12]. Additionally, 78% have a co -occurring mental health diagnosis  [11], which further 
complicates management.  Whether OUD is being under -detected in this population or not 
detected at all, or whether this population is under -reporting OUD, has a primary SUD other than 
OUD, has primary mental health issues other than SUD, or a combination of these factors, is not 
well described. Given the low numbers of individuals with reported OUD in this population, it is 
not surprising that traditional addiction medicine approaches, including those focused on initiating  
MOUD, result in low treatment engagement for NFOO survivors  [11], and misses a prime 
opportunity to intervene with the appreciable proportion of those for whom MOUD is not indicated 
or desired, yet who remain at high risk.  
Given that almost half of NFOO survivors self-report not having substance problems involving 
opi[INVESTIGATOR_2438]  [11], a peer -led support and risk reduction intervention that does not initially focus on 
MOUD engagement or engagement in formal SUD treatment is desirable in this population . Peer 
support specialists who are trained in overdoses and risk mitigation strategies can utilize a 
multitude of non -medication approaches to engage NFOO survivors in behaviors that decrease 
risk for repeat overdose and increase entry into risk -reduction and recovery -based activities  
during the time for highest increased overdose  risk, even if MOUD is not desired nor indicated.  
Additionally, by [CONTACT_9377][INVESTIGATOR_268424], utilizing motivational 
interviewing approaches, peer support specialists can be available to individuals if and when  they 
become ready to engage in formal SUD treatment or higher levels of care.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326752] several years  [13-17]. 
Acknowledging that the post -NFOO population tends to be more difficult to engage with traditional 
medical approaches, several states have developed peer -led ED interventions  to increase 
treatment engagement. Although observational results of these pi[INVESTIGATOR_268425] [13-15, 17] , few have been systematically evaluated.  One such program that has shown 
preliminary promise, developed through Faces and Voices of Recovery (FAVOR) in Greenville, 
South Carolina (SC) , is FAVOR Overdose Recovery Coaching Evaluation (FORCE).  
FORCE is an innovative program using Certified Peer Support Specialists (CPSSs , specific to 
South Carolina ) specially trained in overdose, who are called to the ED as soon as an overdose 
survivor is admitted  and identified . The mission of FORCE is to engage overdose survivors in 
whatever level of contact [CONTACT_268579] (i.e. , ride home, cup of coffee, formal treatment). 
The underlying philosophy of the program is grounded in motivational interviewing, case -
management, health coaching, and assertive community engagement principles . The model 
resembles Strengths Based Case Management Approac h to Patient Navigation used successfully 
in CTN -0049 (HOPE trial) to engage patients, coordinate care, assist pati ents to overcome 
personal barriers, and provide psychosocial and emotional support [18]. Strengths Based Case 
Management has been used effectively to assist individuals linking into as well as maintaining 
substance use treatment.  
In FORCE, the CPSS typi[INVESTIGATOR_268426] O survivor in the ED and  assumes responsibility 
for follow -up after ED discharge . The FORCE CPSS takes on significant responsibility for 
remaining in contact [CONTACT_268580], using a tiered approach, including text, phone, and in -person 
contact. The goal of the outreach is engagement  and linkage to appropriate treatment (SUD or 
otherwise , largely based on the needs and preferences of the client at that time ). A recent study 
evaluated a similar peer recovery coaching in tervention among those who were hospi[INVESTIGATOR_268427] [19] and found impressive rates of treatment 
engagement six months post discharge  (84% vs. 34% in the control condition) . While this study 
shows preliminary promise for intensive peer coaching and assertive community engagement, 
this intervention has not yet been evaluated among those presenting the ED with a NFOO who 
may not meet criteria for a n SUD or OUD  (up to 50% of those presenting with an NFOO) .  
Through the proposed multi -site, randomized, controlled pi[INVESTIGATOR_799], the study  will assess the 
preliminary effectiveness and feasibility of a modified and manualized version of the FORCE 
model, PI[INVESTIGATOR_8571], on overdose risk behaviors (as defined by [CONTACT_268581]) 
and treatment engagement, utilizing a modified SUD Cascade of Care model [20]. 
 Study Rationale  
For those with OUD, it is known that engagement in OUD treatment, longer retention in OUD 
treatment, and utilization of medication is associated with improved outcomes and decreased risk 
of subsequent overdose  [9, 10] . After a n NFOO, there is an initial increased likelihood of SUD 
treatment entry and utilization of buprenorphine. However, even at peak rates of treatment 
engagement – 11% at 1 month for SUD treatment engagement and 3% at 3 months for 
buprenorphine treatment – enga gement is low and  decreases with each additional month after 
overdose  [12]. Moreover, given that less than half of the NFOO population identifies as having an 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
8 OUD, this low level of treatment entry and decline in treatment utilization over time raises the 
critical question of what treatment or risk reduction measures are appropriate for NFOO survivors, 
especially those for whom MOUD is not desired nor indicated, and how to improve the retention 
of those with SUD who enter treatment after an overdose  [21, 22] . The proposed peer -led 
intervention being tested in this study (PI[INVESTIGATOR_8571]) has a distinct advantage in that it can assess and 
address overdose risk factors for those who survive an NFOO regardless of whether the individual 
identifies as having an SUD or is interested or ready for treatment entry.  
Like similar programs  [13-15, 17] , FORCE has demonstrated remarkable preliminary success in 
observational evaluations, with linkage to treatment for 61% of participants in the first [ADDRESS_326753] been 
approached, an d 98% (n=230) agreed to participate in FORCE services, suggesting that 
recruiting overdose survivors from the ED utilizing this model is feasible. Fifty -eight percent of 
engaged clients (133/230) remained actively retained in FORCE at [ADDRESS_326754] 
a monthly check in. Sixty -one percent (140/230) were linked with treatment or other recovery 
support services at some point in time during enrollment. Eight percent of engaged clients 
reported a return to any hospi[INVESTIGATOR_307] “for any reason” (n=19), an d 1.6% died of accidental overdose.  
These encouraging observational results highlight the need for a more rigorous randomized 
controlled trial of peer -led engagement in risk reduction and treatment after overdose  and 
presentation in the ED . While promising, the FORCE intervention has not been adequately tested 
for efficacy, which is the goal of the current trial. To conduct a preliminary test of a peer -led support 
intervention for overdose survivors (PI[INVESTIGATOR_8571]), participants randomized to PI[INVESTIGATOR_268428] [ADDRESS_326755] size determination for a larger randomized 
controlled trial.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
9 
 PRIMARY AIMS, OBJECTIVES , AND HYPOTHESES  
 Overview  
This study is a 2 -arm randomized, prospective pi[INVESTIGATOR_268429] -reported overdose risk behaviors for participants who present to an 
ED after a non -fatal overdose involving opi[INVESTIGATOR_2438] (NFOO).  
A person will  be considered to have experienced  a NFOO if he/she/they self -report affirmatively : 
1. Do you think  you may have experienced an overdose?  
AND  
2. Do you think that overdose may have involved opi[INVESTIGATOR_2438] (heroin, fentanyl, or prescription 
pain medications such as morphine, oxycodone, or hydrocodone) ? 
Those who are considered to have experienced a NFOO according to answers to the questions 
above will be eligible for the study if the self -reported NFOO occurred in the past 30 days and 
other inclusion criteria are met.  
The study will evaluate the frequency of self -reported overdose risk behaviors using a 13-item 
self-report survey (11 items  used to generate a total score; 0 -44 possible points) originally 
modified from a 9-item questionnaire utilized in a pi[INVESTIGATOR_268430] a similar 
population [23] and currently being used in the CTN -[ADDRESS_326756] -overdose 
intervention in [LOCATION_001] City (clinical trials.gov identifier: [STUDY_ID_REMOVED]) . The questionnaire was 
developed and modified  based on known factors associated with risk for overdose, including more 
current overdose risk factors such as fentanyl use [23-33]. The questions measure the frequency  
(over a specified time frame) at which individuals used drugs alone; used in a new 
place/environment; used other substances (alcohol, benzodiazepi[INVESTIGATOR_1651], stimulants) within two ( 2) 
hours of opi[INVESTIGATOR_2438]; used more than one opi[INVESTIGATOR_2480]; used more than the usual amount; and used inhaled 
or injected opi[INVESTIGATOR_2438].  
The study will also secondarily evaluate treatment engagement utilizing a modified SUD Cascade 
of Care, developed for this study, which outlines 10 steps representing different stages of SUD 
treatment engagement ranging from harm reduction to engagement in  SUD treatment to 
improvement in recovery scores (see Section 7.0 , Outcome Measures ). These steps are not 
necessarily sequential nor contingent upon previous steps , but can assess for both informal and 
formal treatment engagement.  
The aims and outcomes of this study are listed below. It should be noted that primary and 
secondary outcomes will be prioritized for publication following study enrollment. Exploratory aims 
will not prevent primary or secondary aims from being disseminated. Additional exploratory aims 
may be possible for analysis after pu blication of the primary and secondary aims of this trial.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326757] at 180 
days ( [ADDRESS_326758]-randomization ). 
 Secondary Aims  
The secondary aims of the study are to: 1) test the hypothesis that PI[INVESTIGATOR_268431] a differing 
number of steps achieved on a modified SUD Cascade of Care at 180 days (6 months) after Index 
ED admission (Secondary Outcome Measure)  as compared with TAU ; and (2) assess whether 
recent NFOO survivors within an ED setting are willing to engage with peer support services , 
measured by (a) the number of potentially eligible patients approached compared with the number 
willing to be enrolled, and (b) the length  of engagement and enrollment in PI[INVESTIGATOR_268432]  (Secondary Outcome Measure).  
 Exploratory Aims  
Exploratory Aim 1:  To assess the effects of PI[INVESTIGATOR_268433] (yes/no) and 
magnitude of achievement ( e.g., improvement in Addiction Recovery Capi[INVESTIGATOR_268434] 3 points , 
number of steps achieved ) on the modified SUD Cascade of Care.  
Exploratory Aim 2:  To evaluate the effectiveness of PI[INVESTIGATOR_268435] (yes/no; assessed via self -report upon ED discharge or in follow -up 
assessment if unable to be assessed at ED discharge).  
Exploratory Aim 3: To assess the effects of PI[INVESTIGATOR_268436] 
30, 90, and 180  days [via self-reported days of illicit opi[INVESTIGATOR_268437] -
Back (TLFB)].  
Exploratory Aim 4: To evaluate the degree of engagement in Peer Support Services in those 
randomized to PI[INVESTIGATOR_268438] 30, 90, and [ADDRESS_326759] month (phone, video , or in-person).  
Exploratory Aim 5: To evaluate the effectiveness of PI[INVESTIGATOR_268439] -reported 
attendance in 12 -step meetings, peer support services, other recognized recovery organization, 
or formal SUD treatment at any time point  during enrollment, defined as self -report of having 
attended a meeting or appointment (phone, video, or in -person).  
Exploratory Aim 6: To evaluate the effect iveness of PI[INVESTIGATOR_268440] 30-, 90-, 180-, and [ADDRESS_326760]-
randomization . 
Exploratory Aim 7: To evaluate the effectiveness of PI[INVESTIGATOR_268441] -fatal 
overdose and 210-day rates of death  (all-cause mortality) , including death by [CONTACT_268582].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
11 
 STUDY DESIGN  
 Overview of Study Design  
 
Figure 2 : Study design.  Additional information about the box in blue  (identification and enrollment 
of study participants) can be found in Figure 1 above.  
This is a 2 -arm, multi -site, randomized, controlled trial evaluating the effectiveness of PI[INVESTIGATOR_268442]-reported overdose risk behaviors at 180 days (6 
months).  
This study will be initiated in the Emergency Department (ED). In addition to routine ED medical 
care, a ll ED sites will have an operationalized peer support system in the ED that will serve as  
part of TAU  (“TAU peer,” though it should be noted that TAU peers may not be available 24  
hours/day) . 
After assessment  and stabilization as part of routine TAU by [CONTACT_175302], a member of the research 
team will approach patients who may qualify for the study , in-person or remotely, for screening, 
consent , and enrollment  in the study . All study sites will have detailed procedures for proper 
identification and recruitment of study participants . All study sites will operate under the MUSC 
policies and procedures for recruitment given the SmartIRB master reliance agreement. As such, 
recruitment procedures will be the same across study sites, with any differences outside of the 
MUSC policies being spec ifically stated and approved as part of local study site standard 
operating procedures (SOPs).  If the participant is eligible an d interested, after consent  and 
determination of eligibility , they will be randomized to either PI[INVESTIGATOR_8571]  (in addition to continuing  TAU)  
or to continue TAU at that time.  
For participants randomized to PI[INVESTIGATOR_8571], in addition to receiving TAU (including possible interaction 
with the TAU peer), there will be an “on -call” system for the PI[INVESTIGATOR_268443] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326761] to complete screening and consent after a patient is discharged from the ED, should the 
potential participant provide verbal consent to be contact[CONTACT_268583] 
. Intervention participants will begin th e PI[INVESTIGATOR_268444], in -person or remotely, 
following the PI[INVESTIGATOR_268445]. PI[INVESTIGATOR_268446] a tiered approach to assertive 
community engagement, utilizing motivational interviewing and Strengths -Based Case 
Management approach to enga ge patients in care and develop a patient -centered 
wellness/recovery plan. The PI[INVESTIGATOR_268447]’s needs (e.g., 
harm reduction, recovery , and treatment resources as they are interested and ready) and will 
involve contac t and interaction with PI[INVESTIGATOR_268448]  (details included in the PI[INVESTIGATOR_268449]) over the course of the 180-day (6 month) treatment period.  Participants randomized to 
TAU will continue TAU and receive any additional standard treatment provided  at the respective 
ED for overdose survivors , including interaction with TAU peer as per hospi[INVESTIGATOR_13707] . All 
participants (TAU and PI[INVESTIGATOR_8571]) will , in the least,  be provided with referral and community resource 
information, consisting of at least : (1) a handout providing names, locations, and telephone 
numbers of addiction treatment services in the area; (2) telephone access to call a clinician or 
facility of their choice, which will be informed by [CONTACT_268584]; and (3) 
information about receiving naloxone  per state regulations and community resources. Addiction 
services can include a range of treatments with varying intensity and duration, based on local 
resources and patient preference. TAU peer s will conduct their standard TAU protocol as they 
would for any other NFOO or substance use patient admitted to the E D, like what is described 
above as an SBIRT -like model common in hospi[INVESTIGATOR_268450] . 
During the site selection process, a thorough assessment will be conducted of each site's 
standard practice for overdoses  and substance -related issues  in the ED and description of peer 
services will be provided  and reviewed (See Section 9.3). 
Throughout the course of the trial, sites will be monitored for any potential changes that might 
occur to TAU around providing resources  and/or treatment  to overdose survivors.  
 Duration of Study and Visit Schedule  
Participants will be engaged in the study for up to 210 days (7 months), which will include 180 
days (6 months) of active intervention (PI[INVESTIGATOR_8571]) or TAU, and a 210 -day follow -up assessment after 
the completion of the intervention. Participants will be assessed at screening/baseline and at 30, 
90, 180, and [ADDRESS_326762] approximately 3 years, 
including site init iation and close -out activities.  
Rationale for Study Duration and Visit Schedule : The purpose of this pi[INVESTIGATOR_254577] (RCT) is to determine the preliminary effectiveness of PI[INVESTIGATOR_8571], including feasibility of 
enrollment, engagement, follow -up and retention, follow -up procedures and preliminary dur ation 
of effect, if effective. Should PI[INVESTIGATOR_268451], an effect size will be determined and used to inform a larger and longer RCT to assess 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326763] after the intervention is 
completed.  
Study visits are scheduled at 30, 90, 180 and 210 days. Based on preliminary results from the 
FORCE  program  and previously published outcomes with inpatients [19], the study  hypothesis is  
that [ADDRESS_326764] participants to demonstrate some benefit from this 
type of intervention. However, it is known that early recovery can be a time of lapses, 
disengagement , and re -engagement. The 30 - and 90 -day assessments allow for evaluat ion of 
participants who may be early responders  and follow them over time to determine duration and 
pattern of engagement. Alternatively, some participants might take several months  to enter  and 
stabilize in recovery, and the overdose risk behav ior scale and modified SUD Cascade of Care 
allow for measurement of earlier incremental or finite achievements within the 180 -day 
intervention period to provide time for those with ambivalence and/or a disengagement/re -
engagement pattern to demonstrate pro gress.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
14 
 OUTCOME MEASURES  
 Primary Outcome Measure  
The Primary Aim of this study is to compare the effectiveness of PI[INVESTIGATOR_268452] 15 0 patients who are admitted to an ED after an NFOO or admitted to the ED with 
an SUD -related issue and self -report recent (past 30 -day) NFOO on the primary outcome of  the 
past month total score on the modified and expanded O verdose Risk Behavior Checklist, which 
captures the frequency of self -reported overdose risk behaviors , at 180 days (6 months). The 
study  will use a modified and expanded version of an Overdose  Risk Behavior Checklist (ORBC) , 
adapted from Bohnert et al. (2016)  [23]. This assessment has been adapted and is being used 
currently in a study focused on risk reduction in NFOO admissions to EDs ( RELAY; 
[STUDY_ID_REMOVED]). The ORBC  that will be used in CTN -0107  is a 1 3-item scale , with  11 of the items 
used to generate a total score (ranging from 0 -44); higher scores will indicate  greater frequency 
and number of overdose risk behaviors. Some items have branching/sub questions, which are 
not included in the total score to allow for the same possible number of points for all study 
participants. These questions will measure risk behaviors in the past month, and the total risk 
score is an aggregation of responses to the specific individual questions.  
 Hypothesis 1 (Primary Outcome Measure):  
The study  hypothesis is  that the PI[INVESTIGATOR_268453] -
reported overdose risk behaviors  (i.e., lower ORBC total score)  via the ORBC at Day 180 after 
randomization compared to TAU.  
 Secondary Outcome Measures  
The secondary outcomes of the study are: 1) number of steps achieved on a modified SUD 
Cascade of Care at 180 days (6 months) after Index ED admission; and (2) engagement with the  
study and  PI[INVESTIGATOR_268422], measured by (a) the number of potentially eligible patients 
approached  compared with the number willing to be enrolled  and (b) the length of engagement  
and enrollment  in PI[INVESTIGATOR_268454] . Length of engagement and 
enrollment is defined as the time from baseline to last meeting with the PI[INVESTIGATOR_268422]/  
counselor.  
Modified SUD Cascade of Care  (Secondary Outcome Measure) :  CASCADE   
OD 
Identification &  
 Harm 
Reduction   
Engagement in 
Care   
MOUD 
Initiation   
MOUD Retention   
Treatment Response & Remission  
(6 month)  STEPS  1 
 
↑ Harm 
Reduction  2 
 
Any 
Care  3 
 
Regular  
Care  4 
 
Any 
MOUD  5 
 
MOUD  
X 1 mo  6 
 
MOUD  
X 3 mo  7 
 
MOUD  
X 6 mo  8 
 
↓ SUD  
Severity  9 
 
Early 
Remission  10 
 
↑ Recovery Score  MEASURE   
Harm Reduction  
Checklist   
Step 2 -7 
Assessment Form 
(SAF 2 -7)  
SAF [ADDRESS_326765]  
Toxicology screen   
Assessment of  
Recovery  
Capi[INVESTIGATOR_268455] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
15 Step Eligibility:  All enrolled participants will be considered to have 0 steps achieved at the time of 
study entry  (baseline) . Acknowledging that individuals will vary in presence and types of SUD 
diagnoses,  this pi[INVESTIGATOR_268456] -type of 
enrolled participant (primary OUD, primary SUD other than OUD, no identified SUD  identified at 
baseline via administration of the DSM -[ADDRESS_326766] ). A participant will be counted as having met a 
particular step if criteria are met at ANY study visit or for any length of time during the study, even 
if the participant subsequently does not endorse a previously endorsed item.  
 Hypothesis 2 (Secondary Outcome Measure)  
PI[INVESTIGATOR_268431] a differing  number of steps achieved along the SUD Cascade of Care at 180 
days  after Index ED admission as compared with TAU. The following will count as attaining a 
step:  
1. Increase in Harm Reduction Exposure and Behaviors : A participant will have attained 
Step [ADDRESS_326767]  assessment : (1) any unchecked box 
becomes checked , (2) total score of checked boxes increases from baseline at any time 
during study (even if score subsequently decreases) , or (3), if the Narcan availability  
item is checked as “Often ” or “Very Often ” at baseline and remains checked at  any other 
study visit  OR becomes checked as “Often ” or “Very Often ” at any visit subsequent to 
base line. This assessment can be completed in person, electronically, or over the 
phone. A participant will be counted as having met Step 1  if the above criteria are met at 
ANY study visit, even if the participant subsequently does not meet the step criteria or 
does not endorse a previously endorsed item.  
2. Engagement in care – Any: A participant will have attained Step [ADDRESS_326768] month ( through the Steps 2 -7 Assessment Form ): 
(a) scheduling a formal SUD treatment appointment; (b) attending an in -person or on -
line recovery or 12 -step meeting (AA, NA, SMART, Celebrate Recovery, In the Rooms, 
etc.); (c) attending an in -person, virtual or phone session with a peer recovery speci alist; 
(d) attending at an in -person or virtual formal SUD treatment appointment (medication 
and/or psychosocial treatment, including outpatient, intensive outpatient or residential 
treatment). Step 2  will be assessed throughout the 6 -month treatment and 7-month 
follow -up visit. A participant will be counted as having met Step 2  (at study visits after 
baseline assessment) if the above criteria are met at ANY non-baseline study visit  
(through 180 days) , even if the participant subsequently does not meet the step criteria 
or does not endorse a previously endorsed item  (i.e., any engagement in care) . 
3. Engagement in care – Regular:  A participant will have attained Step [ADDRESS_326769] 90 
days . A participant will be counted as having met Step 3  (after baseline assessment)  if 
the above criteria  are met  for any length of time during the study, even if the participant 
subsequently does not meet the step criteria or does not endorse a previously endorsed 
item.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
16 4. Taking MOUD – Any: A participant will have attained Step 4  (after baseline assessment) 
if the y self-report taking any dose of MOUD (no confirmation needed, but self -repor t of at 
least one dose ). A participant will be counted as having met Step [ADDRESS_326770] 30 days : A participant will have attained Step [ADDRESS_326771] 30 days AND toxicology screen (s) 
are positive for buprenorphine or methadone, consistent with self -report, as confirmed at 
study visits. If (1) the participant self -reports taking naltrexone, or if (2) the toxicology 
screen (s) are negative, unable to be obtained, or inconsistent with self -report ( e.g., a 
participant did not take MOUD in past 10 days, but did take MOUD the previous 20 
days), Step 5  can also be confirmed by [CONTACT_5640] (a) confirmation with treatmen t provider or 
pharmacy of prescription written and/or dispensed consistent with MOUD availability [ADDRESS_326772] 30 days; OR (b) participant providing the prescription bottle at the study visit 
or video  chat (utilizing HIPAA -compliant platform) of a prescription bottle including 
matching name, medication, and date dispensed consistent with MOUD availability [ADDRESS_326773] 30 days prior to the study visit (can be provided up to 90 days  after the 
scheduled study visit). A participant will be counted as having  met Step 5  (after baseline 
assessment) if the above criteria  are met  for any length of time during the study, even if 
the participant subsequently does not endorse a previously endorsed item.  
6. Taking MOUD consistently over the past  90 days : A participant will have attained Step [ADDRESS_326774] 90 days AND  
toxicology screen (s) are positive for buprenorphine or methadone, consistent with self -
report. If (1) the participant self -reports taking naltrexone, or if (2) the  toxicology screen 
is negative, unable to be obtained, or inconsistent with self -report, this step can be 
confirmed by [CONTACT_5640] (a) confirmation with treatment provider or pharmacy of  prescription 
written and/or dispensed consistent with MOUD availability [ADDRESS_326775] 90 days; OR 
(b) participant providing the prescription bottle at the study visit or a video  chat (utilizing 
HIPAA -compliant platform) of the prescription bottle including name, medication, and 
date dispensed consistent with MOUD availability [ADDRESS_326776] 90 days (can be 
provided up to 90 days  after the scheduled study visit). A participant will be counted as 
having met Step 6  if the above criteria  are met  for any lengt h of time during the study, 
even if the participant subsequently does not endorse a previously endorsed item.  
7. Taking MOUD consistently for 180 days : A participant will have attained Step [ADDRESS_326777] 180 days  AND this is 
confirmed  by [CONTACT_5640] (a) confirmation with treatment provider or pharmacy; (b) providing 
the prescription bottle at the study visit or a video (utilizing HIPAA -compliant platform) of 
the prescription bottle including name, medication, and date dispensed (can be prov ided 
up to 90 days  after the scheduled study visit); OR (c) 30-day + 90-day + 180-day 
toxicology screen positive for buprenorphine or methadone, consistent with self -report. If 
(1) the participant self -reports taking naltrexone, or if (2) the toxicology screen (s) are 
negative, unable to be obtained, or inconsistent with self -report, this step can be 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
17 confirmed by [CONTACT_5640] (a) confirmation with treatment provider or pharmacy of prescription 
written and/or dispensed consistent with MOUD availability [ADDRESS_326778] 180 days; OR 
(b) participant providing the prescription bottle at the study visit or a video  (utilizing 
HIPAA -compliant platform) of the prescription bottle including name, medication, and 
date dispensed consistent with MOUD availability [ADDRESS_326779] 180 days . Step 7  will 
only be available to those who are retained in the study and complete th e 180-day study 
visit. 
8. Decrease SUD Severity : A participant will achieve Step [ADDRESS_326780] for the primary SUD decreases as compared with 
baseline at the 30 -, 60- OR 180 -day visit. A participant will be counted as having met 
Step 8  if the number of criteria decreases below the baseline score at ANY study visit, 
even if there is/was an increase in number of DSM -5 criterion met at previous or 
subsequent study visits.  
9. Early Remission : A participant will have achieved Step [ADDRESS_326781] met criteria for 
Step 9  even if remission is not achieved in each SUD identified.  
10. Increase in Recovery Capi[INVESTIGATOR_307] S core: A participant will have achieved Step 10  if the total 
score on the Assessment of Recovery Capi[INVESTIGATOR_307] (ARC) scale  [34] (range 0 -50) increases 
by a value equivalent to 0.[ADDRESS_326782] deviations within  the validation sample, which was 
11.54  [22] (5.77 point increase  or greater  needed to meet Step 10), from baseline to the 
30- 90- OR 180 -day visit. A participant will be counted as having met Step 10  if they 
increase above the baseline score at ANY study visit even if there is/was a decrease in 
ARC at previous or subsequent study visits.  
If the algorithm is unclear regarding whether  a specific step was achieved post -randomization, it 
will be adjudicated by [CONTACT_268585].  
 Other Outcome Measures  
Exploratory Aim 1:  To assess the effects of PI[INVESTIGATOR_268433] (yes/no) and 
magnitude of achievement ( e.g., improvement in Addiction Recovery Capi[INVESTIGATOR_268434] 3 points, 
number of steps achieved) on the modified SUD Cascade of Care.  
Exploratory Aim 2:  To evaluate the effectiveness of PI[INVESTIGATOR_268435] (yes/no; assessed via self -report upon ED discharge or in follow -up 
assessment if unable to be assessed at ED discharge).  
Exploratory Aim 3: To assess the effects of PI[INVESTIGATOR_268436] 
30, 90, and 180  days [via self -reported days of illicit opi[INVESTIGATOR_268437] -
Back (TLFB)].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
18 Exploratory Aim 4: To evaluate the degree of engagement in Peer Support Services in those 
randomized to PI[INVESTIGATOR_268438] 30, 90, and [ADDRESS_326783] month (phone, video , or in-person).  
Exploratory Aim 5: To evaluate the effectiveness of PI[INVESTIGATOR_268439] -reported 
attendance in 12 -step meetings, peer support services, other recognized recovery organization, 
or formal SUD treatment at any time point  during enrollment, defined as self -report of having 
attended a meeting or appointment (phone, video, or in -person).  
Exploratory Aim 6: To evaluate the effectiveness of PI[INVESTIGATOR_268457].  
Exploratory Aim 7: To evaluate the effectiveness of PI[INVESTIGATOR_268441] -fatal 
overdose and 210-day rates of death (all -cause mortality), including death by [CONTACT_268582] . 
 Pi[INVESTIGATOR_268458] a pi[INVESTIGATOR_799] , this protocol  is designed to inform  a larger, multi -site randomized trial . All 
procedures employed in the pi[INVESTIGATOR_268459] t est those  procedures intended for 
implementation  in the subsequent larger trial [10]. 
As part of the pi[INVESTIGATOR_268460] [35], the study  aims  will be to  identify, record , and correct for 
obstacles or “lessons learned”  that may interfere  with success ful implementation  of the larger 
randomized trial  [10]. In keepi[INVESTIGATOR_41244], four milestones  have been identified to improve  
readiness to advance  to a larger study , which has been informed by [CONTACT_268586] [14]. Additionally, the study will s ystematically track the obstacles encountered 
and lessons learned during implementation of this pi[INVESTIGATOR_268461]. 
Milestone 1 : Conver t the FORCE  intervention  to a manual -based PI[INVESTIGATOR_268462]. This milestone will be defined as successfully identifying and 
manualizing key components of the FORCE intervention  into a PI[INVESTIGATOR_268463] . This will be 
accomplished through identification of key components and development of a preliminary 
intervention manual by [CONTACT_153142] 107 Team, including Rich Jones as the peer intervention expert. 
The key components and manual may be vetted by [CONTACT_268587].  During the training and implementation phase of the 
study, the study will also assess the ability to train personnel to implement the intervention with 
acceptable competence  during the study . 
Milestone 2 : Identif y critical site operational elements needed to successfully recruit for and 
conduct this trial in an ED setting and successfu lly replica te these critical elements in 3 sites.  This 
Milestone will be addressed by [CONTACT_268588]  (e.g., adequate 
numbers of reported overdoses presenting to the ED, adequate identification of overdose 
survivors in the ED, adequate space in the ED for peers, peers hav ing lived experience with 
substance use, naloxone education and distribution, etc.).  Investigation  of these elements will 
initially occur during site selection  (which wi ll define baseline TAU ) and  will be implemented  by 
[CONTACT_268589] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326784] or are able to implement 75% of  critical P ILOT  site elements . 
Anticipated and actual recruitment will be monitored to inform whether the presence of critical site 
elements leads to successful recruitment. In addition, any changes in the presence or availability 
of these critical site elements, including any changes in TAU during the study period, will be 
measured quarterly to assess for sustainability of the critical elements and natural evolution of 
TAU.  
Milestone 3:  Investigate surrogate/composite markers of overdose  to estimate sample size for a 
larger trial powered for mortality outcomes.  The current pi[INVESTIGATOR_268464] -reported NFO Os, fatal overdoses as 
reported by [CONTACT_268590] ( Section 1 1.3.5 ), and the National Center for Health Statistics’ 
National Death Index , the latter of which will be examined  after the study end s, as it takes greater 
than one year for the data to be available in this database  (Section 1 1.6). The study will also 
evaluate  initiation of MOUD as part of the secondary outcome (SUD Cascade of Care), as utilizing 
MOUD i s known to be associated with decreased mortality for those with OUD (surrogate 
outcome).  Lastly, the study will measure  overdose risk behaviors known to be associated with 
repeat overdose and death ( e.g., fentanyl use, intravenous drug use ). Changes in each of these 
surrogate markers  will be evaluated to determine which markers , or which composite of these 
markers , will best predict mortality.  
Milestone 4 : Determine the p reliminary effectiveness of PI[INVESTIGATOR_268465] (surrogate overdose marker ). The study predict s that there will be a greater reduction 
in overdose risk behaviors in the PI[INVESTIGATOR_268466]. It would follow that a 
decrease in behaviors known to be associated with overdose risk would lead to a decrease in 
subsequent repeat overdose, a mor e distal outcome  to be fully powered  in the larger study . This 
Milestone will be defined  as detecting a 10% low er rate of overdose risk behaviors in PI[INVESTIGATOR_268467] (any subgroup) as compared to TAU.  
 Study Timeline  
After receiving CCTN  and PRB  approval of the protocol, approximately 6-8 months of trial 
preparation activities will elapse prior to commencing study enrollment . Trial preparation will 
include obtaining IRB approval  (single IRB proposed) , developi[INVESTIGATOR_268468], 
developi[INVESTIGATOR_268469], developi[INVESTIGATOR_268470], conducting 
all staff training, endorsing sites. Sites will be launched  in a single wave  if possible . Recruitment 
is expected to take approximately 12 months  (approximately 4.2 participants enrolled per month 
per site; approximately N=15 0), with follow -up continuing for [ADDRESS_326785] completion of the 
recruitment phase. Approximately six  months will be allowed for data  cleaning and data  lock after 
the end of the follow -up period. Therefore, data lock is projected to occur at approximately 2 7 
months after PRB approval of the protocol.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326786] 30 days will be randomized ( approximately 50 per each of 3 
sites). Study staff will confirm self -reported overdose with the participant, and those who confirm 
an NFOO meeting the criteria below will be eligible. Those who are initiated on MOUD in the ED 
will be included. Randomized participants will  be stratified by [CONTACT_268591] . 
Non-Fatal Overdose Involving Opi[INVESTIGATOR_2438] (NFOO) Description:  
A person will  be considered to have experienced  a NFOO if he/she/they self -report affirmatively:  
1. Do you think you may have experienced an overdose?  
AND  
2. Do you think that  overdose may have involve d opi[INVESTIGATOR_2438] (heroin, fentanyl, or prescription 
pain medications such as morphine, oxycodone, or hydrocodone) ? 
Those who are considered to have experienced a NFOO according to answers to the questions 
above will be eligible for the study if the self -reported NFOO occurred in the past 30 days and 
other inclusion criteria are met. An overdose does not need to be conf irmed for the participant to 
be included but  should be self -reported as an overdose involving opi[INVESTIGATOR_268471]. Alternative definitions for an overdose  were considered; however, it 
was decided  that this definition will appropriately identify the desired  population for inclusion . In 
addition, the definition is consistent  with current practice to identify OD survivors. Patients may 
be in the ED for an overdose event or for another SUD -related event if the NFOO occurred in the 
past [ADDRESS_326787] : 
1. Be [ADDRESS_326788] by [CONTACT_3647]  (no upper age limit 
for inclusion).  
2. Meet one of the following non -fatal overdose involving opi[INVESTIGATOR_2438] (NFOO) criteria:  
a. Having presented to the Emergency Department for any health issue within the 
past [ADDRESS_326789] 30 days  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326790] two 
individual contacts other than the participant .  
4. Be able to speak English sufficiently to understand the study procedures and provide 
written informed consent to participate in the study  as determined by [CONTACT_3647] .  
5. Be w illing and able to confirm future SUD treatment receipt as evidenced by 2 out of 3 of 
the following: (a) signing appropriate releases to for study staff to confirm treatment with 
follow -up provider; ( b) having technology necessary to visualize  medication bottles and 
transmit to study team utilizing HIPAA -compliant platform; and/or ( c) able and willing to 
undergo toxicology tests (in person or via HIPAA -compliant videoconferencing).  
 Participant Exclusion Criteria  
Exclusion criteria include those who are : 
1. Identified as having had an intentional  overdose as the Index NFOO.  
2. Actively suicidal  at the time of screening  (defined as current intention and/or plan for 
suicide attempt) . 
3. Unable to complete study baseline procedures due to medical or psychiatric condition.  
4. Currently in jail, prison or in police custody at the time of the index ED visit or under 
current terms of civil commitment or guardianship  (i.e., OHRP -defined prisoner status) . 
5. Previously randomized as a participant in th is study – individuals may only be enrolled 
and randomized once.  
6. Unwilling to follow study procedures (e.g., unable to provide sufficient locator information  
[defined as two contacts]  or unavailable for follow -up assessments).  
 Rationale for Inclusion/Exclusion  
Including those without known SUD or primary SUD other than OUD : Although the most common 
SUD diagnoses in those with NFOO is OUD [11, 12]  and a diagnosis of OUD is a stronger risk 
factor for repeat overdose than having other SUDs or no SUD, the following is the rationale for 
including those with no currently identified SUD or other primary SUDs: (1) the prevalence of SUD 
diagnosis in an ove rdose population presenting to the ED is not well described; (2) NFOO 
survivors without SUD/OUD do have increased risk of repeat OD; (3) NFOO survivors with no 
identified SUD or SUDs other than OUD may still/particularly benefit from a peer -based 
intervent ion addressing overdose risk reduction; and (4) individuals, particularly those on 
prescription opi[INVESTIGATOR_2438], may not initially acknowledge criteria for SUD, but later do so. For the 
purposes of this pi[INVESTIGATOR_799], those with no identified SUD or primary SUD othe r than OUD will be 
included, and since it has been shown that NFOO survivors without SUD/OUD are less likely to 
engage with outreach efforts  [11], the primary outcome measure, screening and PI[INVESTIGATOR_268472].  
Secondarily, several steps on the SUD Cascade of Care can be achieved by [CONTACT_268592]/desired, which will also be measured.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
22 Excluding active suicidality and intentional/suicidal overdose attempts  at screening : Because 
most overdose deaths involving opi[INVESTIGATOR_268473] [36], and because managing an individual 
immediately after an intentional  overdose is outside the scope of standard peer support service  
practice s, individuals reporting that the Index NFOO was intentional, as well as those who are 
actively suicidal, will be excluded. Any participant who scores >0 (“not at all”) on question 9 of the 
Patient Health Questionnaire -9 (PHQ -9; “Over the last [ADDRESS_326791] you been 
bothered by [CONTACT_33687]?  Thoughts that you would be better off dead or of 
hurting yourself in some way ?”) will have their suicidal ideation assessed  by a medical clinician . 
Those with active suicidal ideation will be managed by [CONTACT_268593]. Those with “passive” suicidal ideation, defined as 
hopelessness and/or passive wish for or indifference about death, without current suicide plan or 
intention, will be eligible, as these symptoms are relatively common in those with active SUD.  
Including those admitted to the hospi[INVESTIGATOR_268474] : Those admitted to the 
hospi[INVESTIGATOR_268475] (if able to 
meet other inclusion criteria), as it is the current practice of FORCE CPSSs to follow participants 
during hospi[INVESTIGATOR_268476].  
Including those discharged from the ED before screening can be completed : Some individuals 
may be identified as potential candidates for the study, but either leave Against Medical Advice  
(AMA)  or are discharged from the ED before screening can be completed. If study staff are able , 
with verbal consent, to contact [CONTACT_268594] a NFOO within 72 hours  of ED discharge, 
they can be screened for entry into the study  and can be enrolled within one week of the ED 
discharge . 
 Strategies for Recruitment  and Retention  
Participants will be recruited from the ED at the time of ED admission  (primary method of 
recruitment) . Recruitment, approaching patients , screening, consent , and study procedures can 
be completed in -person or remotely, utilizing HIPAA -compliant videoconferencing and approved 
tele-consenting platforms as applicable. There will be two sources of referral: (1) During routine 
clinical care, patients presenting wit h or identified or suspected of having experienced an 
overdose in the past 72 hours, as identified  by [CONTACT_175302], including medical providers and TAU 
peers , can be referred for study screening; and (2) Research study staff will follow ED 
trackboards, coordinate with TAU peers  and ED staff to screen for and identify individuals who 
may have experienced an overdose in the past [ADDRESS_326792] operating procedures (SOPs) .  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
23 
 Recruitment p rovisions for modified operations due to COVID -
19, other population -level safety concerns , or low enrollment at 
sites: 
[IP_ADDRESS]  Remote Recruitment/ Enrollment  
If restrictions to in -person patient care occur due to infectious diseases , such as COVID -19, or if 
ED patient flow slow s due to other population -level safety concerns, potential research 
participants will be able to be identified and recruited in the ED utilizing remote techniques, 
including HIPAA -secure videoconferencing and /or approved tele -consenting via REDCap . All 
study procedures would be the same except the method of communication. For remote 
procedures, participating EDs will be provided with an electronic device (such as a “smartphone” 
or iPad) sufficient for HIPAA -compliant research consenting and procedures.  
Additionally, if potential participants are identified within the ED, but unable to be reached 
remotely in the ED, research staff , with verbal consent,  can follow -up with the participant after ED 
discharge, if the individual can be contact[CONTACT_11252] 72 hours of ED discharge ; which mirrors the 
in-person contact [CONTACT_268595].  
The method of recruitment and enrollment (in -person, remote, or both) will be tracked for each 
participant and summarized for scheduled DSMB meetings.  
The remainder of the study outside of recruitment is desig ned for remote study completion. 
Regular in -services and/or educational briefings will be provided to ED staff to familiarize them 
with the study eligibility criteria.  
It will take sites approximately 12 months to enroll the proposed sample into this study. The 
average weekly randomization rate across all three sites is expected t o be 1-2 
participants/week/site  (4.25 per month proposed for each site).  
[IP_ADDRESS]  Community Recruitment  
If site recruitment goals in the ED are below -goal for two or more consecutive months, after 
discussion with the Lead Team, a site may be able to commence recruitment efforts in the 
community  (e.g., recruit and enroll participants outside of the ED setting) , with all 
screening/enrollment/ study procedure s completed remotely . This will only be pursued in the case 
of modified operations or restrictions in the hospi[INVESTIGATOR_268477] /or a failure to identify NFOO 
survivors to engage regarding study enrollment. The m ethod of recruitment and enrollment (ED 
or community) will be tracked for each participant and summarized for scheduled DSMB 
meetings.  The following will be the modified Inclusion/Exclusion Criteria for Community 
Recruitment:  
[IP_ADDRESS]  Modified Inclusion/Exclusion Criteria for Community 
Recruitment  
To be included in this study , participants recruited from the community must : 
1. Be [ADDRESS_326793] by [CONTACT_3647]  (no upper age limit 
for inclusion) .  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326794] two 
contacts other than the participant .  
4. Be able to speak English sufficiently to understand the study procedures and provide 
written informed consent to participate in the study  as determined by [CONTACT_3647] .  
5. Be w illing and able to confirm future SUD treatment receipt as evidenced by 2 out of 3 of 
the following: (a) signing appropriate releases to for study staff to confirm treatment with 
follow -up provider; ( b) having technology necessary to visualize medication bottles and 
transmit to study team utilizing HIPAA -compliant platform; and/or ( c) able and willing to 
undergo toxicology tests (in person or via HIPAA -compliant videoconferencing).  
Exclusion criteria for those recruited from the community include those who are : 
1. Identified as having had an intentional  overdose as the Index NFOO.  
2. Actively suicidal  at the time of screening  (defined as current intention and/or plan for 
suicide attempt) . 
3. Unable to complete study baseline procedures due to medical or psychiatric condition.  
4. Currently in jail, prison or in police custody at the time of the index ED visit or under 
current terms of civil commitment or guardianship  (i.e., OHRP -defined prisoner status) . 
5. Previously randomized as a participant in th is study – individuals may only be enrolled 
and randomized once.  
6. Unwilling to follow study procedures (e.g., unable to provide sufficient locator information  
[defined as two contacts]  or unavailable for the follow -up assessments).  
Participants recruited from the community who are randomized to TAU will receive , from the 
research study staff, a referral to treatment, consisting of a handout providing names, locations, 
and telephone numbers of addiction treatment services and naloxone resources in the area and 
telephone access to call a clinician or facility of their choice, which will be inform ed by [CONTACT_268596] . Addiction services can include a range of treatments with varying intensity 
and duration, based on local resources and patient preference.  
Community -recruited participants randomized to PI[INVESTIGATOR_268478] -person with the on -call PI[INVESTIGATOR_268411], according to the PI[INVESTIGATOR_268445] . 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
25 
 SITE SELECTION  
 Number of Sites  
In this pi[INVESTIGATOR_799], participants will be recruited from three  sites in the US  over a 12 -month period . 
The study period will be seven months  (6-month intervention  period  and 1 -month follow -up 
assessment  at Day 210 ). 
 Site Characteristics  
Three sites that already have established and funded Peer Recovery Services in their ED (TAU) 
will participate in the study. Sites will be screened for willingness to  deliver PI[INVESTIGATOR_8571], willingness to 
randomize patients in PI[INVESTIGATOR_268479]. TAU , and current numbers of patient who are admitted to the ED 
with an identifiable overdose per month.  
Participating sites should:  
1. Have sufficient numbers of  ED admissions with an identifiable overdose to randomize 1 -
2 participants per week  during study enrollment  (4.2 per month proposed for each site).  
2. Currently provide peer support services in the ED for overdose survivors or those with 
an SUD  that do  not regularly follow participants into the community  (preferably a single 
point of contact [CONTACT_268597]).  
3. Provide adequate space in the ED or in a nearby [CONTACT_268598] . 
4. Be able to provide after -hours clinical backup for study -related emergencies . 
5. Be willing to deliver the manualized PI[INVESTIGATOR_268422] . 
6. Have the ability  to provide naloxone kits and/or information on obtaining naloxone to 
patients per state regulations.  
7. Meet 75% of critical site characteristics as determined by [CONTACT_268599] 2. 
8. Have an ED champi[INVESTIGATOR_268480], 
processes , or engagement by [CONTACT_175302].  
 Rationale for Site Selection  
Sites that already have ED peer recovery services in place will be utilized because the successful 
operationalization of a peer recovery intervention in an ED setting is a separate endeavor outside 
the scope of this pi[INVESTIGATOR_799] (which will evaluate the eff ectiveness of a specialized overdose peer 
who engages with participants in the ED AND follows participants into the community). To 
evaluate the effectiveness of the PI[INVESTIGATOR_268422] (which is a separate question from how to 
effectively operationalize a s uccessful peer team in an ED setting), the study  will start with the 
premise that peer support services have already been successfully operationalized and are 
functional to serve as a comparator group.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326795] insurance.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
27 
 STUDY PROCEDURES  
 Screening  
Patients will be recruited at each ED site, either in -person or via remote techniques  (if needed) . 
Study sites will operate under the MUSC policies and procedures for recruitment given the 
SmartIRB master reliance agreement. As such, recruitment procedures will be the same across 
study sites, with any differences outside of the MUSC policies being speci fically stated and 
approved as part of local study site standard operating procedures (SOPs). Research staff will 
work during times to include evenings and w eekends to ensure success with enrollment. 
Research staff will identify patients seen in the ED by [CONTACT_15249], reviewing the EHR trackboards 
and by [CONTACT_268600]. Research staff will keep a log of all patients approached 
and the outcome of that approach (Screening  and Approach  Log). Potential participants identified 
will be evaluated by a member of the research staff for eligibility.  
Patients will be  stabilized per ED usual care and receive TAU per that ED site, noting that each 
site will have an operationalized peer support specialist system already in place in the ED which 
may be a part of TAU (Figure 1 ). After clinical stabilization  and TAU , research staff  will ask  for 
verbal consent to complete screening forms  and assessments , which will include questions about 
overdose s in the past 30 days , reason for the ED visit, and other items that may exclude that 
individual from study inclusion . Research staff will follow an approved verbal consent script which 
details how their information might be used/exceptions to confidentiality based on urgent medical 
concerns  during the screening process .  
Patients who appear to be eligible will then be asked about interest in the study. If the answer is 
yes, research staff will describe the study and if the participa nt remains interested and would like 
to continue, written informed consent will begin . 
Those who are not eligible for the study following screening questions or who decline w ill continue 
with TAU in the ED ( including additional interaction with a TAU peer from the hospi[INVESTIGATOR_307] , as 
applicable; all  participants in the least will receive a referral list of options  for follow -up care , 
access to a telephone,  and information about obtaining naloxone ). Those who do not qualify for 
the study or decline participation will have the option to fill out a brief anonymous survey to 
elucidate characteristics of  suspected overdose and reasons for study decline  (Screening Exit 
Survey) . A waiver of signed consent will be acquired  from the Medical University of South Carolina 
(MUSC) Institutional Review Board (IRB)  to administer this brief survey for reasons for study 
refusal and to maintain and use patient characteristic data.  Those who complete the Screening 
Exit Survey will be compensated $15. Identifying information will be collected to compensate 
participants but will not be linked with their survey responses. This information may be used to 
better inform recruitment strategies, evaluate feasibility of the peer intervention  program  in the 
ED from a participant -interest standpoint, and be used to contrast characteristics of consent ing 
and non -consenting individuals.  
 Eligibility Confirmation  and Enrollment   
After the Screening Enrollment Form has been completed and the patient  meets basic eligibility 
criteria, they will be asked to give written informed consent . 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326796] for the study , and the study will  comply with all 
necessary requirements at each site. Each site will use the IRB -approved Informed Consent.  
The informed consent procedures will be flexible to accommodate the needs of patients admitted 
to the ED. Candidates for study participation will be provided a copy of the current IRB -approved 
consent form for review. An appropriately qualified and trained  individual will explain the study 
procedures  and the potential risks and benefits of participating in the trial, as well as  answer all  
the candidate’s questions about the study. Staff will be available to answer questions about the 
consent form while part icipants are reviewing it.  Participants will be asked to explain the study in 
their own words ( consent teach -back form) to research staff . This will not be exclusionary but  will 
aid in determining that consent is informed and understood.  
Because of the time constraints of completing the assessment and initial intervention in the ED, 
the informed consent form will be as brief as possible within the constraints of adequate human 
subjects’ protections. These documents will include a descripti on of the following key elements: 
general study procedures ; the follow -up interviews; risks and benefits of the PI[INVESTIGATOR_268481]; alternatives to participation in the study; confidentiality; compensation for 
participation; a statemen t that participation is voluntary and that they may freely withdraw 
participation at any time; and information about whom to contact [CONTACT_268601]. The Informed Consent includes assurances of confidentiality (including a Certificat e 
of Confidentiality) , as well as exceptions to confidentiality, and that the decision to participate will 
in no way influence other aspects of the patient’s treatment.  
If recruitment and study procedures are being completed remotely, REDCap electronic consent 
(e-consent) , combined with a HIPAA -secure video  conferencing platform , will be used  during the 
consent process (preferred). Participants are also able to view  the informed consent document 
on a computer or phone via REDCap and complete a phone call with research staff. Video chat 
functionality will only be used if all parties have the availability and is not required for consent to 
be performed . Each study site will have their own MUSC REDCap database managed by [CONTACT_268602]. Using these systems, signatures on the consent form may be obtained 
electronically via REDCap .  
Participants will also be asked  for locator information for self, relatives , or friends to enable the 
study staff to find them during the [ADDRESS_326797] the participant in the future about other study opportunities.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326798] 
Release Forms  
Each site will utilize a Research Authorization, HIPAA disclosure form  and/or 42 CFR Part 2 
allowing study access to confirm engagement in SUD treatment, as required by [CONTACT_268603].  
Sites will be responsible for communicating with their IRBs or Privacy Boards and obtaining the 
appropriate approvals or waivers to be in regulatory compliance with local requirements.  
 Eligibility Confirmation, Screening , and Baseline Assessment s 
After screening eligibility is confirmed, the patient will be entered into the data system to complete 
inclusion/exclusion information, and to confirm eligibility. The enrollment procedures will be 
captured through a centralized process managed by [CONTACT_200824] (DSC). 
Study patients who do not complete all screening  assessments or who are otherwise found to be 
ineligible for participation in the study will be considered screen failures.  
The site’s research team will review screening assessments to determine final eligibility for 
randomization. In most instances screening and baseline assessments may be p erformed during 
the same visit, and randomization will occur at that same visit (typi[INVESTIGATOR_897]).  
 Randomization  
Eligible participants will be randomized in a 1:1 ratio to PI[INVESTIGATOR_268482]. Randomization will be stratified by [CONTACT_268604]  (yes/no).  The randomization process will be conducted in a centralized 
process through the DSC. A permuted block randomization procedure with random block sizes 
will be implemented to balance per site  and homelessness status , and randomization details such 
as block size will not be conveyed to sta ff or participants. The DSC statistician will generate the 
randomization schedule using balanced blocks of varying sizes within strata to ensure lack of 
predictability along with relative equality of assignment across treatment groups. The block size 
also will be randomized to prevent the potential for study personnel guessing the next assignment 
which sometimes happens with a fixed block -size. 
Randomization will be performed by a designated study staff member over the internet using the 
Enrollment Module in Advantage eClinical. The DSC statistician will review the randomization 
data on a regular basis to ensure that the scheme is being implement ed according to plan. If a 
participant drops out of the study at any point after randomization, the randomization slot will not 
be re -allocated to a new patient due to the intent -to-treat nature of the study.  
 Treatment/Intervention  
In this study, participants will be randomized to PI[INVESTIGATOR_268409].  Medical care and management of 
the overdose or medical issue will be treated the same across both groups and will not be 
impacted by [CONTACT_70973].  
Baseline assessments will be collected through participant interviews and a toxicology screen. 
Management of OUD, if present, will be managed based on standard of care in the hospi[INVESTIGATOR_268483]. A TAU peer system will be operational in  each ED site and will interact 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
30 with participants across both groups in an SBIRT -like model as indicated and available at that 
site. 
TAU:  For the purposes of this study, TAU is defined as usual medical treatment , including MOUD 
if indicated/available  and any TAU peer support services as offered per standard practice at the 
site ED. Research staff  will administer baseline assessments and toxicology screen during the 
ED Index visit and arrange for 30 -. 90, and 180 -day study visits to occur via phone and/or 
community visit and/or video chat.  Participants randomized to TAU will continue receiving local 
standard of care through time of ED dis charge/transfer.  
PI[INVESTIGATOR_8571]:  After randomization has occurred, for individuals randomized to PI[INVESTIGATOR_8571], a PI[INVESTIGATOR_268484] a phone call/video chat will be 
organized. Participants randomized to PI[INVESTIGATOR_268485] d of care (TAU), as 
well as the PI[INVESTIGATOR_268422]. This may mean that PI[INVESTIGATOR_268486] a 
TAU peer and a PI[INVESTIGATOR_268487] a recommended collaboration process will be formalized with 
each site based on site characteristi cs. 
The PI[INVESTIGATOR_268488] 6-
month  treatment period . PI[INVESTIGATOR_8571] w ill begin after study randomization  and the PI[INVESTIGATOR_268489] -up visits per the PI[INVESTIGATOR_268490]. The PI[INVESTIGATOR_268491] . Research staff will administer 
baseline assessments and toxicology screen during the Index visit and arrange for 30-, 90-, and 
180-day study visits to occur via phone and/or community visit and/or video chat.  
The research staff will also record key clinical elements provided during ED visit (e .g., MOUD 
applicable/offered  [via study CRF] , TAU peer meeting , and resources provided [captured on the 
study visit checklist] ). 
 30-, 90-, and [ADDRESS_326799] randomization . The day of randomization will be considered study Day 0. 
Follow -up visits may be completed in person at the site or  via telephone, video chat, and/or 
electronic communication  by [CONTACT_464]. Additionally, research staff will have the option to meet 
participants at a convenient location in the community to collect study assessments and data , if 
necessary . Research staff safety protocols for community visits will be implemented  for research 
study visits (detailed in the study MOP and local site SOPs) and  can include  the following:  at least 
2 staff members attending the visit  at all times ; providing location information for the study visit;  
checking in immediately with supervisors before and after visits have occurred ; and prioritizing 
meetings in public spaces . 
Reminders regarding study visits  will be given to the participant several times leading up to their 
next study visits ( using  email, phone call , or text based on the preference of the participant) . In 
addition, research staff will send a reminder in the mail/text/email/phone or social media (based 
on study participant preferences documented on the locator information form) approximately 
seven days before  the scheduled follow -up visit, with an additional reminder notification via 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
31 mail/text/email/phone /social media (based on study participant preference) the day before the 
scheduled follow -up visit. 
Study visits will entail collection of self -report data, questionnaires, interview questions, and oral 
fluid toxicology testing. Self -report, questionnaire, and interview data will center on substance 
use, engagement with recovery and/or formal SUD treatment, including medications, and 
overdoses during the interim period. Appropriate release of information will b e obtained to confirm 
treatment engagement if needed. These assessments are listed in Section 11  and their flow is 
operationalized in the study MOP. 
If a participant is unable to utilize a phone for any reason during any study assessments, research 
staff will utilize locator information to arrange to meet the participant in the community, according 
to MOP criteria, to administer study assessments and toxicology sample collection.  
 Weekly Mobile Surveys  
To augment data collection in this trial, remote surveys will be administered to participants on 
their mobile devices using  the Research electronic data capture (REDCap) system [37], which is 
available to MUSC investigators and external affiliates (i.e., all site research staff) . REDCap is a 
HIPAA -compliant, cloud -based, commercial off the shelf data management system that can be 
used for creating and distributing surveys . Remote surveys will be administered to participants 
following randomization and will not occur on weeks when study visits are scheduled (Day s 30, 
90, 180, and 210). Given that only four study visits are scheduled during  this trial, data collection 
between visits  is critical for capturing  a more accurate pi[INVESTIGATOR_268492], the recovery 
process , and steps taken in the cascade of care.  
Remote s urveys on REDCap  will be delivered to the participant’s mobile phone as a survey invite 
link through an SMS text message. Surveys will be administered weekly . The survey invite  
includes an individualized link that contains embedded data, at individually calibrated time points. 
If the participant does not have a smartphone (anticipated to be <10% of participants) , they will 
be able to borrow one during the study. Responses will be date and time -stamped  and p articipants 
will receive compensation  for completing each remote  survey .  
 Follow -Up Assessment  (Day 210)  
Participants will be followed for 210 days (7 months) after randomization (180 days/6 months of 
Intervention, and a one -month /Day [ADDRESS_326800]-intervention follow -up). Assertive outreach 
procedures will be implemented to locate and assess participants at the follow -up time  point and 
to minimize missing data. These procedures are detailed in the study MOP.  Arrangements for 
ongoing treatment following the study will occur as per local practice. There will be flexibility in 
exact timing of the intervention assessm ents to accommodate participants’ schedules and to allow 
for either in -person or electronic communication (e.g., phone, video chat, community visit, etc.).  
 Premature Withdrawal of Participants  
All participants will be followe d for the duration of their 210 -day (7 -month) participation in the study 
unless they withdraw consent, die, or the investigator or sponsor decides to discontinue their 
enrollment for any reason. Reasons for the investigator or sponsor terminating a participant from 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326801] options (e.g., phone, address, email, social media) a nd collateral contact 
[CONTACT_268605]. At any time, participants may decide that they no longer wish to 
continue to participate in the study.  
 Study Halting Rules  
This study entails a single point of intervention, randomization to PI[INVESTIGATOR_268409]. The use of Peer 
Support Services in assisting those with SUD is a low -risk intervention that is clinically well -
established  [13-15, 17] . The study does not anticipate  any circumstances that would necessitate 
halting the study based on safety or efficacy. There are no plans to conduct an interim efficacy 
analysis or sample size re -estimation as part of this trial. Nevertheless, the study DSMB or the 
study sponsor may choose to halt the study should they identify issues related to study conduct, 
funding, or regulatory environment. Should this occur, the lead investigator will work with the IRB 
of record and each of t he local sites to promptl y inform them of the reasons for study termination 
or temporary suspension and to identify the circumstances in which the study may resume.  
 Blinding  
No blinding will be used for the interventions  in the PI[INVESTIGATOR_268493] . The lead team will ensure that 
all research staff, peers, and any affiliated staff have proper training on minimizing bias in 
unblinded trials. The next randomization assignment will not be known to research staff, peers, 
or ED staff. The assigned group w ill not be known until all screening  data have been entered into 
the study database and the randomization assignment is generated and provided to the research 
staff. Research staff will not be able to predict the next randomization spot given that the other 
study sites will affect randomization ordering. This will help to minimize bias among study staff.  
 Participant Reimbursement  
Because of the expected difficulty of maintaining high follow -up rates in the study population, 
adequate compensation for time and inconvenience is critical. Compensation will be in 
accordance with the IRB of record’s policies and procedures, subject to IR B approval, and will 
occur on the following schedule , and allowances can be made for pro -rated compensation for 
study sessions that are interrupted or completed on different days : 
• Consent and baseline data collection  
• 30-day assessmen t 
• 90-day assessment  
• 180-day assessment  
• Follow -up assessment ( Day 210 ) 
• Remote assessment compensation: 24 surveys administered  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326802] an option to complete a brief survey to 
evaluate reasons for study decline or screen -out and will be compensated according to the MOP.  
Compensation will occur following each visit with procedures  and payment practices specified in 
the MOP  and local site SOPs . 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326803] 
feasibility and to minimize assessment reactivity that can obscure treatment effects [38]. The  
practical issue is that extensive study assessments are likely to interfere with the rapid pace of 
clinical treatment in the ED setting. A cumbersome assessment process is also likely to impede 
the successful completion of the study through an adverse imp act on recruitment and would not 
be part of real -world clinical practice. Excluding collection of study participant characteristics and 
locator information, the patient baseline data will include a brief instrument assessing overdose 
events, past 7 -day alcohol and drug use including opi[INVESTIGATOR_268494] (TLFB) 
method, use of other substances, and overdose risk factors. The Table of Assessments (shown 
below) provides a summary of  study assessments. The expected time burden for the screening 
and baseline assessments is around 2-[ADDRESS_326804] randomization will be similar in content and will be kept brief.  
 Table  1: Table  of Assessments /Forms  
Assessment  Time Needed 
to Complete  
(only for ppt 
assessments ) 
Screen ing 
Random -
ization  
Baseline  
Day 30  
Day 90  
Day 180  
Day 210  
As Needed  
(Index ED 
Visit/Enrollment)  – 
Virtual or In -person  Phone , 
Virtual, 
or In -
person  Phone , 
Virtual, 
or In -
person  Phone , 
Virtual, 
or In -
person  Phone , 
Virtual, 
or In -
person  
Screening  
Screening Enrollment Form  5 mins X        
Prisoner Status Assessment  2 mins  X        
Demographics  5 min  X        
Patient Health Questionnaire -9 2 mins  X   X X X X  
Screening Exit Survey  10 mins  X        
Written Informed Consent  30-45 mins  X        
Inclusion/Randomization  and Study Visits  
Study Enrollment Form    X       
Visit Documentation     X X X X X  
Locator Information Form  5-10 mins    X [X] [X] [X]  [X] 
Overdose Information  [ADDRESS_326805]  3 mins    X X X X X  
Step 2 -7 Assessment Form  
(SAF 2 -7) 4 mins    X X X X X  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
35 Assessment  Time Needed 
to Complete  
(only for ppt 
assessments ) 
Screen ing 
Random -
ization  
Baseline  
Day 30  
Day 90  
Day 180  
Day 210  
As Needed  
(Index ED 
Visit/Enrollment)  – 
Virtual or In -person  Phone , 
Virtual, 
or In -
person  Phone , 
Virtual, 
or In -
person  Phone , 
Virtual, 
or In -
person  Phone , 
Virtual, 
or In -
person  
MOUD Confirmation 
Assessment ( confirmed via 
objective measures)  3 mins     X X X X  
MOUD  Current  Status  2 mins    X X X X X  
Readiness Ruler  1 min    X X X X X  
Alcohol and Substance Use 
History  (PhenX Tier 1)  10 mins    X      
Timeline Follow -Back (7 day)  [ADDRESS_326806]  5-10 mins    X X  X X  X  
ED MOUD Administration 
(obtained from EMR)     X      
End of Treatment        X  X 
Assessment of Recovery 
Capi[INVESTIGATOR_307]  [ADDRESS_326807] Log  5 mins         X 
Death Form  5 mins         X 
Protocol Deviation  and Review 
Forms  5 mins         X 
Study Completion  Form  2 mins        X X 
Inventory – Supplies Form  5 mins         X 
TAU Characterization Form  15-20 mins         X 
Peer Characterization Survey  5-10 mins         X 
Remote Assessments  
Mobile Weekly Surveys  3-5 mins     Xb Xb Xb Xb  
PI[INVESTIGATOR_268495] 1-5 mins    X X X X X  
Supervisor Log  3-5 mins        X  
Rolling Progress Note  2-10 mins        X  
Notes : b=administered weekly  
[X]= assessment is reviewed and updated as needed  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326808] 30 
days, the Screening Enrollment Form asks whether the overdose was accidental or intentional. If 
the individual’s answer is “intentional”, the individual will be excluded from study participation, but 
the response will also prompt study staff to have the individual evaluated by [CONTACT_268606] -Up Assessment Form.  
The Screen Enrollment form also documents eligibility during the screening phase, before written 
informed consent is obtained. Eligibility will be re -assessed prior to randomization, and then 
continually as appropriate. Only participants who continue to meet study eligibility c riteria will be 
allowed to continue with the screening process and randomization.  
 Prisoner Status Assessment  
Individuals approached in the ED  will complete a Prisoner Status Assessment to determine that 
they do not meet the OHRP definition of prisoner. If they do meet the definition, they will not be 
able to enter the study, but will continue to receive TAU as established in the ED . The individual  
is not assigned a number and no data is retained from the encounter. If the individual  does not 
meet the definition of prisoner, they will be invited to learn more about the study and complete the 
informed consent proces s. 
 Demographics Form  
The PhenX Demographics form collects information about demographic characteristics of the 
participant, including sex, date of birth, ethnicity, race, education, employment status, and marital 
status. A study -specific demographics form collects information about homelessness, criminal 
justice supervision, employment, insurance status, living arrangements, etc.  
 Alcohol and Substance Use History ( PhenX Tier 1 ) 
The Substance Abuse and Addiction Collection of the PhenX Toolkit 
(http://www.phenxtoolkit.org/ ) includes measures that are being adopted across NIDA -funded 
research. The Core Tier [ADDRESS_326809] up to date version of 
the PhenX questions will be used (Version 20, dated December 2019).  
This form will be administered at baseline only and will assess lifetime and past [ADDRESS_326810] use. For the 
baseline assessment, this form will be administered contiguous with the 7 -day TLFB  to avoid  
repeat assessment of drug use.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
37 
 Informed Consent and Research Authorization  
Participants will review and sign the IRB -approved consent form and any other related documents 
(e.g., Research Authorization, HIPAA authorization) in accordance with IRB requirements  either 
in person or electronically through REDCap eConsent . Procedures for obtaining informed consent 
and related authorizations are detailed in Sections 10.[ADDRESS_326811] s information regarding eligibility 
Only participants who continue to meet study eligibility criteria will be allowed to continue with 
randomization.  
 Screening Exit Survey  
Patients who do not pass the screening  instrument and/or are not interested in participating in the 
study will have the option to complete a brief, de -identified , interviewer -administer ed survey 
asking about reasons for ED visit, demographics, substance use history, overdose history, Narcan 
availability, and reasons for study decline (as applicable) . Compensation will be provided for 
completing this survey, but as the survey will not be associated with identifying information, it will 
be completed with an a pproved waiver of written consent.  
 General Measures  
 Patient Health Questionnaire (PHQ -9) 
The Patient Health Questionnaire (PHQ -9) [39] will be used to assess depressive symptoms, 
includ ing suicidal ideation. If the participant responds to “Thoughts that you would be better off 
dead, or of hurting yourself in some way” with any response other than “Not at all”, it will trigger a 
requirement to provide the participant with  Suicide Hotline information and other mental health 
resource  information  per the MOP . When the response is recorded at screening/baseline , the 
study clinician, or in cases where the study clinician is not reasonably avail able, an available non -
study clinician at the site  will be notified. All sites should monitor participant responses to this 
PHQ -9 question , as well as participant spontaneous express ion of  potential suicidal/homicidal 
ideation  and have procedures in place to ensure patient safety.  In all cases, participant mental 
health follow -up should occur according to site -specific SOPs. For any endorsement of potential 
suicidal ideation reported on the PHQ -9, completion of the Mental Health Follow -up Assessment 
form will be required.  
 Visit Documentation  
This form documents visit attendance , non -visit attendance , and missed visits . This form 
additionally captures whether any ED visits or hospi[INVESTIGATOR_268496], 
and if so, it triggers the ED Visit and Hospi[INVESTIGATOR_268497] . This assessment has been recently 
developed to document visits that could occur out of window, off site, or missed due to COVID -
19. This is a visit -based form expected at all visits that would typi[INVESTIGATOR_44769] a regular missed visit 
form. If a visit is missed for any reason, this form will capture the reason a study visit was missed. 
Completing this form and indicating that the visit was not attended will remove the requirement 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
38 for all assessments scheduled for that visit. Active tracking and follow -up should be performed for 
all missed visits. The form also captures specific data collection settings if applicable (such as in 
clinic, off -site, remote , or in a controlled environment).  
 Locator Information Form  
A locator form is used to obtain information to assist in finding participants during treatment and 
at 30 -, 90-, and 180 -day phone assessments as well as a 210 -day follow -up assessment. This 
form collects the participant’s current address, email address, a nd phone numbers (updated 
frequently or as needed)  as well as information such as social security number, driver’s license 
number and other information to aid in searches of public records . To facilitate locating 
participants and keepi[INVESTIGATOR_158002] -to-date phone n umbers if direct contact [CONTACT_200843], 
addresses and phone numbers of family/friends or other contacts who may know how to reach 
the participant are collected (minimum of two required to be eligible for the study). This information 
will be coll ected at after obtaining informed consent and will be updated at each visit or whenever 
the participant reports a change in locator information. No information from this form is used in 
data analyses. At screening/baseline, at least two contacts must be id entified.  
 MOUD Current Status  
This form will be used to assess current MOUD use, and if affirmative, MOUD formulation, dose, 
and date of last dose.  
 Timeline Follow -Back (TLFB)  
The Timeline Follow -Back  [40] procedure will be used to elicit the participant’s self -reported 
frequency of use and route of administration of nicotine, opi[INVESTIGATOR_2438], marijuana, stimulants, 
benzodiazepi[INVESTIGATOR_1651] , sedatives, hallucinogens, inhalants,  and alcohol for the past seven days. At 
enrollment, substance use will be reported by [CONTACT_212555] 7 -day period prior to informed 
consent. At the 30 -, 90-, 180 -, and 210 -day follow -up visit, substance use is reported for 7 days 
prior to the visi t date. This will be completed remotely or duri ng in -person visits.  These procedures 
will also be used to capture days of MOUD use (yes/no) during the entire study period.  
 DSM -[ADDRESS_326812] 12 months, and if affirmative, assesses for the presence of 11 
symptoms of substance use disorders  based on DSM -5 diagnostic criteria including: opi[INVESTIGATOR_2480], 
alcohol, amphetamine, cocaine, cannabis, and sedative s. If SUD is endorse d, participants will be 
asked about primary substance of use . 
 ED MOUD  
This form will record information regarding medications for OUD administered during the index 
ED admission, according to patient self -report at the time of ED discharge, including medication 
name (methadone, SL buprenorphine, SL buprenorphine/naloxone, ora l naltrexone, and 
extended -release naltrexone), date, and total dose administered (if known). This data will be used 
to determine MOUD exposure in the ED Index visit.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
39 
 End of Treatment Form  
This form tracks the participant’s status regarding  the study intervention. It will be completed at 
the end -of-treatment visit or at the 180 -Day visit (for participants who complete study 
participation).  
 Quality of Life (Qol)  
Quality of life  will be measured using  a standard form  used in the CTN, the CDC Behavioral  Risk 
Factor Surveillance System (BRFSS) HRQOL -4). This measures general health of the participant 
and healthy days out of the last month (physical and mental health) . 
 Crime and Criminal Justice  
This form captures data on incarceration, recent crimes, and recent contact [CONTACT_268607].  
 Treatment/Study Satisfaction Form  
Participants will complete a Treatment/Study Satisfaction Form at the 210 -Day visit. This form will 
assess the acceptability of study procedures, time, compensation, treatment intervention and 
other aspects of their experience.  
 ED Visits and Hospi[INVESTIGATOR_268498] (inpatient and outpatient) between the index and 
30-, 90-, 180 -, and 210 -day assessments and on an as needed basis for spontaneous reporting 
that occurs between study visits. ED visits and hospi[INVESTIGATOR_268499] -report 
and review of participant electronic medical records.  
 Chronic Pain History  
This brief questionnaire evaluates the presence of self -reported chronic pain (6 months or longer) 
and average daily pain severity.  
 Study Completion Form  
This form tracks the participant’s status in the study. It is completed at the 210 -Day visit , after the 
210-Day follow -up visit window lapses for participants who do not complete this final follow -up, or 
after the site confirms that a participant is permanently done with the study (e.g., participant died 
or withdrew consent). This form is used in data analyses to address variables such as treatment 
retention and completion. This form also provides a location for  the site PI [INVESTIGATOR_268500] y data.  
 Measures of Primary and Secondary Outcomes  
 Overdose Risk Behavior Checklist (ORBC; Primary Outcome )  
The Overdose  Risk Behavior Checklist (O RBC)  is an expanded and modified 13-item self -
administered questionnaire  that was adapted specifically for this pi[INVESTIGATOR_268501]  [23, 24] , and developed based on known factors associated with risk for overdose  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
40 [23, 28 -33]. The questions measure the frequency  at which individuals used drugs alone; used in 
a new place/environment; used other substances (alcohol, benzodiazepi[INVESTIGATOR_1651], stimulants) within 2 
hours of opi[INVESTIGATOR_2438]; used more than one opi[INVESTIGATOR_2480]; used more than the usual amount; and used inhaled 
or injected opi[INVESTIGATOR_2438] . Some branching/sub questions exist, which are not counted in the total score 
or item number count. The total risk score  (ranging from 0 -44 based on 11 items ) is an aggregation 
of responses to specific  individual questions, with higher levels indicating a greater frequency and 
number of overdose risk behaviors. The overdose risk behavior questionnaire is administered at 
scheduled study visits .  
 Steps Achi eved Along SUD Cascade of Care Assessment 
Battery (Secondary Outcome)  
At 30, 90,  180, [ADDRESS_326813], Steps Achieved Assessment (Step 2 -7 Assessment Form), MOUD 
Confirmation Assessment, DSM -[ADDRESS_326814], and the 
Assessment of Recovery Capi[INVESTIGATOR_307] (ARC) Scale.   
 Harm Reduction Checklist  
The Harm Reduction Checklist was developed specifically for this pi[INVESTIGATOR_4251]. Th is form  compi[INVESTIGATOR_268502] -related overdose. The HRC constitutes Step 1 
of the secondary outcome (SUD Cascade of Care). Step 1 – Receipt of and Participation in Harm 
Reduction Services – includes items assessing a range of  harm reduction services such as receipt 
of harm reduction psychoeducation, Narcan, fentanyl test strips, and treatment for comorbid 
health and mental health conditions.  This form also assesses for prescribed opi[INVESTIGATOR_105849], 
with formulation and dose, as applicable.  
 Step 2 -7 Assessment Form  
This form was developed specifically for the PI[INVESTIGATOR_268503]’s engagement in Steps 2 -7 on the Cascade of Care  (research staff  administered) . This 
form will assess engagement in care/treatment  and frequency of attendance (Step 2 measures 
“any” care/treatment attendance; Step 3 measures “regular” care/treatment attendance), as well 
as initiation of MOUD (Step 4) and duration on MOUD  (Steps 5-7; based on an assessment of 
frequency of MOUD use and confirmation per MOUD Confirmation Assessment ). Although this 
form will  be administered at baseline for descriptive purposes, it will only be used for the Steps 
Achieved Along SUD Cascade of Care Assessment Battery at 30-, 90-, 180-, and [ADDRESS_326815] 
enrollment, as applicable.  
 MOUD Confirmation Form  
This form will be used to document confirmation of MOUD through toxicology screen, treatment 
provider or pharmacy confirmation, or via HIPAA -compliant photo or video chat confirmation of a 
MOUD medication bottle or prescription. This form will also be used  to document any issues 
encountered with video capture of MOUD confirmation (poor connection, poor lighting, no sound, 
etc.). MOUD confirmation must be verified through objective means and cannot be self -reported 
by [CONTACT_2299].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
41 
 Assessment of Recovery Capi[INVESTIGATOR_307] (ARC) Scale [34]  
This validated assessment quantifies addiction recovery strengths through 10 domains and 
captures the personal and environmental resources that are associated with recovery (known as 
recovery capi[INVESTIGATOR_307]). Responses on this form will be used to inform progress  on the Cascade of Care.  
 Exploratory Outcomes  
 Overdose Information  [41] 
At baseline, 30-, 90-, 180-, and 210-days  post enrollment, participants  will be asked about lifetime 
overdose experiences (baseline) or opi[INVESTIGATOR_2480] -related overdose events  since the time of the last study 
visit (30-, 90-, 180 - and 210 -day). This form will date, quantify , and describe  overdose events 
experienced as well as general symptoms/outcomes of overdoses experienced (e.g., Was Narcan 
administered? Did the overdose result in ED visit or hospi[INVESTIGATOR_059] ?). 
 Death Form  
Data will be collected on all -cause mortality, including fatal overdose, with information from 
persons listed on the participant’s locator form when participants are lost to follow -up throughout 
the study. Attempt s will be made to contact [CONTACT_268608] -up throughout 
their visit windows (until Day 210 follow -up visit).   
 National Death Index  
Attempt will be made to account for all participants who may have died during the study or after 
the study ends, by [CONTACT_268609]’ (part of the Centers for 
Disease Control and Prevention) National Death Index. This is a list of all persons who have died 
in the U.S. Data . After the study has ended, identifiable information will be used , including  name, 
date of birth, sex, social security number, state of residence  to search this database for death and 
cause ; specific cons ent for use of PHI after the study ends will be obtained from the participant  
during the informed consent . Records in the  NDI database are delayed by [ADDRESS_326816] 30 days will be asked  whether the index overdose was accidental or intentional. If the 
individual’s answer is “intentional”, the individual will be excluded from study participation, but the 
response will also prompt study staff to have the individual evaluated by [CONTACT_268610] -Up Assessment Form.  
The PHQ -[ADDRESS_326817] had “thoughts that you would be better off dead, or of 
hurting yourself in some way” over the past two weeks. During screening  in the ED , any response 
to the above question other than “Not at all”  will prompt the research staff  to notify  the study 
clinician or, in cases where the study clinician  is not reasonably available, a non -study clinician at 
the site  (per verbal pre -screening script and Informed Consent) . If subsequent clinician evaluation  
reveals that the patient has current, “active” suicidal ideation, then the patient will not be eligible 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
42 for the study . However, c ontinued assessment and/or intervention for patient’s  suicidality will  still 
be conducted in accordance  with TAU in that ED and  with site-specific  SOPs . The treating ED 
staff should be made aware of the individual’s suicidality if not already known, and this will be  
discussed in both the verbal screening script and Informed Consent .  
After enrollment in the study and during subsequent study visits  (conducted remotely or offsite 
within the community ), participant endorsement of potential suicidal ideation either on the PHQ -9 
or spontaneously will trigger a requirement to provide the participant with national or local mental 
health resource referral/contact [CONTACT_3031] (e.g., suicide hotline information) per the MOP .  
In all cases, endorsement of possible suicidal ideation on the Screening Enrollment Form and 
PHQ -9 will trigger a requirement for completion of a n MHA  Mental Health Follow -Up Assessment 
form. A protocol deviation is required if this form is not completed , or the above procedures  are 
not followed. Note : the Mental Health Follow -Up Assessment form is not completed  when the 
participant reports potential suicidal ideation outside the context of the Screening Enrollment Form 
or PHQ -9 assessment (e.g., through spontaneous expression, interaction with peer support 
specialists, or other clinical encounters) . However, m ental health resources will still be provided 
to participants in these cases , with additional response/follow -up dictated by [CONTACT_3725]-specific SOPs .  
 Protocol Deviation Data  
 Protocol Deviation and Review Form  
This form should be entered into the electronic data capture system whenever a protocol deviation 
occurs. This form will document a description of the deviation, how it occurred, the corrective 
action taken to resolve the specific deviation, as well as a d escription of the plan implemented to 
prevent future occurrences of similar deviations . This form will also capture if protocol deviations 
were a result of COVID -[ADDRESS_326818] kits 
following all the manufacturer's recommended procedures. Toxicology screens  will test  for the 
presence of commonly used drugs  (including, but not limited to opi[INVESTIGATOR_858], oxycodone, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], cocaine, amphetamines, methamphetamines, marijuana, methadone, 
buprenorphine, and fentany l).  
 Readiness Ruler  
This brief form will assess the participants readiness for and confidence in making a change to 
reduce overdose risk behaviors . 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326819] for Nicotine Dependence [42] 
This assessment is a brief, validated questionnair e to assess nicotine dependence, which will be 
collected to supplement the tobacco use history form being collected via the PhenX Toolkit 
assessment battery.  
 Cannabis Use Assessment  
This form assesses use of marijuana/cannabis for medical purposes, marijuana exposure items, 
and medical issues or symptomology that marijuana is being used to treat/manage.  
 Weekly Mobile Surveys  
Remote assessments via weekly mobile surveys will be kept brief to encourage compliance. 
Survey items (delivered via SMS text message to the participant  and completed via REDCap ) will 
include; self -reported opi[INVESTIGATOR_2441], injection drug use, use/engagement in treatment or medications 
(MOUD), any use of other drugs  or alcohol  in the past week (yes/no), overdose risk behavior or 
mitigation (using drugs alone, Narcan access), and any prescription opi[INVESTIGATOR_27251] (prescribed or 
not). 
 PI[INVESTIGATOR_268504] -delivered interventions during 
the study. The PI[INVESTIGATOR_268505] a participant and/or family/support person, check -off which interventions were 
performed, and quantify time spent on intervention(s). This form will also allow for weekly 
accounting  of other peer activities such as presenting the participant in supervision; assessing 
participant’s engagement and SUD status; a nd assessing participant’s progress, response to 
treatment, and ongoing risks.  
 Supervisor Log  
This form serves as the main log for the peer supervisor to document and assess each peer 
support specialist’s participation in supervision as well as grade fidelity to the main components 
of the PI[INVESTIGATOR_268399].  
 Study Site Surveys  
TAU Characterization: The TAU characterization survey serves to document changes in sites’ 
overdose ED TAU procedures throughout the study. Research staff will interview appropriate TAU 
or ED personnel who can speak to TAU procedures for this survey (i.e.,  TAU peers, ED staff, Site 
PIs, etc.). No identifying information will be collected on these surveys. Surveys will be completed 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
44 prior to site initiation, quarterly throughout the study, and once after enrollment and follow -up is 
completed. Individuals interviewed will provide verbal consent to speak with site research staff.  
 PI[INVESTIGATOR_268506] s, one asking about basic 
demographics and one  regarding their training history, background, and perceptions and views 
on recovery and harm reduction. The second  survey will ask personal questions about the peer’s 
history, and again, will be anonymous. These data will be de -identified and captured in REDCap 
The second survey will be repeated at study completion . A public survey link  will be sent to the 
peer’s email address  (all at the same time to av oid identifying any responses).  One member of 
the research team will have access to the database and d ata will not be viewed until the end of 
study enrollment by [CONTACT_268611] . Peers do not need to complete the 
survey s if they do not feel comfortable , and the lead research team will not know who has 
responded. Language will be included in the survey to indicate that by [CONTACT_268612].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326820] matter experts, as applicable.  
The CTN -0107 study staff will be trained as specified in the study Training Plan. Training will 
include Human Subjects Protection (HSP) and Good Clinical Practice (GCP) as well as protocol -
specific training on assessments, study interventions, safety and targeted safety event reporting, 
study visits and procedures, data management, quality assurance, etc. The Lead Node is 
primarily responsible for development and delivery of study -specific training related to the study 
intervention(s) and procedures. The CC C is responsible for the development and delivery of non -
intervention training, including regulatory and any laboratory procedures, safety and targeted 
safety event reporting, quality assurance and monitoring, etc. The DSC is responsible for training 
related to data management (DM), the electronic data capture system, and good DM practices. 
Other parties will contribute as needed based on the subject matt er and material to be covered. 
The various sub -teams will collaborate to deliver quality instructional m aterial designed to prepare 
research staff to fully perform study procedures based on the assigned research roles and 
responsibilities.  
In addition to general and study -specific training, the Training Plan will include a description of 
the delivery methods to be used for each training module (e.g., via self -study, online, webcast, or 
teleconference). Study staff is required to complete ins titutionally required training per their 
research site, Institutional Review Board(s), and authorities with regulatory oversight. Tracking of 
training completion for individual staff as prescribed for assigned study role(s) will be documented, 
endorsed by [CONTACT_1377] [INVESTIGATOR_268507], and audited by [CONTACT_145859]. As 
changes occur in the prescribed training, the Training Plan and training documentation tracking 
forms will be amended to reflect these adjustments.   
 Training, Supervision, and Fidelity Monitoring Procedures for Study 
Interventions  
 Selection of Interventionists/Care Facilitators  
Three  PI[INVESTIGATOR_268508] , with one peer specialist serving as 
the “Lead Peer.”  The Lead Node will provide a sample job posting for Peer Support Specialists . 
Ideally, PI[INVESTIGATOR_268509]: 1) experience as a peer support 
specialist ; 2) familiarity with opi[INVESTIGATOR_268510]; 3) knowledge of local resources for substance use treatment; and 4) a 
high comfort level in venturing out in to the field not only to build and maintain rapport with care or 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326821] to follow -up. 
Attention will be paid to hiring PI[INVESTIGATOR_268511]’s substance using overdose population. The lead team will provide consultation as needed to 
local nodes and ED sites during the selection process.  
 Selection of Expert Trainers  
The lead team is a varied group of investigators with depth and breadth of experience in OUD 
treatment, peer interventions for SUD and OD populations, and other peer, community 
engagement, and care coordination interventions, intervention training and supervision, and 
quality assurance (QA) monitoring. The lead team will also seek out consultants in designing and 
implementing the training  (National Intervention Team) . A training work group will be established 
and will be responsible for ensuring that the ap propriate training is provided by [CONTACT_268613].  
 Training of Certified Peer Support Specialists  
All PI[INVESTIGATOR_268512] a nationally recognized  CPSS 
certificate  (or equivalent based on the state) . The study training of PI[INVESTIGATOR_268513]: 1) pre -national training  and pre -peer training ; 2) in-person or remote peer training; and 
3) post -peer and post-national training.  The PI[INVESTIGATOR_268514] -
study national training, which will be virtual. The PI[INVESTIGATOR_268515].  
Pre-national training and pre -peer training will occur using  conference calls, webinars, written 
materials , and self -study and will help prepare PI[INVESTIGATOR_268516]. The pre -national training will provide instruction on the overall CTN -[ADDRESS_326822] participants with 
services . 
The national training will occur in one location, in-person or virtually (if necessary), or a hybrid of 
virtual and in -person sessions. PI[INVESTIGATOR_268517]. The peer training will include all PI[INVESTIGATOR_268518] (role -play) training using  the PI[INVESTIGATOR_268445]. The 
training will include a discussion of PI[INVESTIGATOR_268519], responsibilities, and boundaries; detailed 
overv iews of each treatment group; appropriate communication techniques such as asking open -
ended questions, paraphrasing, summarizing, and rolling with resistance; role -plays of various 
participant/care facilitator meetings with receipt of immediate feedback ; and importance of active 
supervision . 
Post-national training  and post -peer training  will occur via conference calls, webinars, and/or 
written materials with the purpose of providing additional support and guidance on intervention 
delivery and to assist Peers  in preparing for trial launch.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
47 
 Treatment Fidelity (Evaluation of Treatment Integrity)  
Supervision of Staff Conducting the PI[INVESTIGATOR_268399]:  
Given the spontaneous nature of peer -participant engagement and the fluidity of the PI[INVESTIGATOR_268520], PI[INVESTIGATOR_268521]. However, PI[INVESTIGATOR_268522]. During supervision, supervisors will monitor and evaluate fidelity to the main 
components of the Intervention in the Supervisor Log, which will be scored and reviewed by [CONTACT_268614] , as well as supervisor notes  that will also be reviewed . Feedback from 
supervision  will be provided to the interventionist. The National Intervention Director will conduct 
regularly scheduled conference calls to discuss difficulties and successes in providing PI[INVESTIGATOR_268523] ; to facilitate learning from and supporting each other; and to facilitate receiving support 
and feedback from the National Intervention Director. Interventionists will be invited to seek 
additional consultation with the National Intervention Director via phone or em ail as intervention 
issues arise.  
Quality Control of the PI[INVESTIGATOR_268399]:  
Quality control of the PI[INVESTIGATOR_268524]: 1) since  
much of the contact [CONTACT_976][INVESTIGATOR_268525], the Lead PI[INVESTIGATOR_268526] a day to shadow the PI[INVESTIGATOR_268527]; and 2) the Lead PI[INVESTIGATOR_268411], study research staff , QA monitors , 
and/or lead study team members will routinely review the Peer Intervention Log  to ensure that 
PI[INVESTIGATOR_268528].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
48 
 CONCOMITANT THERAPY /INTERVENTION  
 General  
Prior to enrolling in CTN -0107, participants may have pre -existing relationships with professionals 
and paraprofessionals involved with SUD treatment, including a medical provider, CPSS, 12 -step 
sponsor, and/or a social worker. Renewed or continued contact  [CONTACT_268615]. Regardless 
of study group, impeding any such contacts would be both unethical and infeasible. To account 
for non -study related professional or  paraprofessional contacts, participants will be asked about 
such exposures during follow -up assessments.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
49 
 STATISTICAL DESIGN AND ANALYSE S 
 General Design  
This study is a 2 -arm, pragmatic, randomized, prospective pi[INVESTIGATOR_268529] -reported overdose risk behaviors at 180 
days after Index ED admission.  
 Study Hypothesis and Objectives  
The primary hypothesis of this trial is that PI[INVESTIGATOR_268431] a reduction in self -reported overdose 
risk behaviors at 180 days after Index ED admission as compared with TAU.  
Key secondary hypotheses are that PI[INVESTIGATOR_268431] a reduction of self -reported overdose risk 
behaviors at 30 days and 90 days, with the same hypothesis above, but at the different month 
time points.  
The secondary objective of the trial includes the following : 
1. Assess number of steps achieved along a modified SUD Cascade of Care for those 
randomized to PI[INVESTIGATOR_268479]. TAU.  
2. Assess whether NFOO survivors within an ED setting are willing to engage in study 
procedures and with peer support services using the PI[INVESTIGATOR_268530] .  
Exploratory objectives include the following. In situations of comparison between TAU and PI[INVESTIGATOR_8571], 
the null hypothesis is that there is no difference between the two, and the alternative is that there 
is a difference.  
1. Assess the effects of PI[INVESTIGATOR_268531] [ADDRESS_326823] month.  
5. Evaluate the effectiveness of PI[INVESTIGATOR_268439] -reported attendance in 12 -step 
meetings, peer support services, other recognized recovery organization, or formal SUD 
treatment at any time  during study participation.  
6. Evaluate the effectiveness of PI[INVESTIGATOR_268532].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
50 7. Evaluate the effectiveness of PI[INVESTIGATOR_268441] -fatal overdose and 210-
day rates of death.  
The primary outcome measure for the primary objective and key secondary hypotheses is the 
frequency of self -reported overdose risk behaviors at 180 days after Index ED admission as 
defined in Section 7.1, measured as a total score  from 11 items  ranging from 0 to 44. 
The outcome measures for the secondary objectives are : 
1. Number of steps achieved on the modified SUD Cascade of Care  
2. Number accepting the intervention (to possibly engage with CPPSs using the PI[INVESTIGATOR_268533]) compared with number approached  
3. Length of time from baseline to last meeting with the PI[INVESTIGATOR_268422]/counselor  
Participants will be recruited at each ED site. Research staff assigned to the study will work during 
times to include evenings and weekends to ensure success with enrollment. Research staff will 
identify patients seen in the ED by [CONTACT_15249], reviewing the  ED trackboards, and by [CONTACT_268616]. A member of the research team will keep a log of all patients screened and excluded 
and the reasons for exclusion. Potential participants identified will be evaluated by [CONTACT_268617].  
 Randomization and Factors for Stratification  
Eligible participants will be randomized in a 1:[ADDRESS_326824] been completed. The randomization process will 
be performed by [CONTACT_268618]. A permuted block random ization procedure with random 
block sizes will be implemented to balance per site and homelessness status (yes/no).  
The randomization procedure will be conducted centrally through the DSC, and randomization 
details such as block size will not be conveyed to staff or participants. The DSC statistician will 
generate the randomization schedule using balanced blocks of vary ing sizes within strata to 
ensure lack of predictability along with relative equality of assignment across treatment groups. 
The DSC statistician will review randomization data on a regular basis to ensure that the scheme 
is being implemented according to plan. If a participant drops out of the study at any point after 
randomization, the randomization slot will not be re -allocated to a new patient due to the intent -
to-treat nature of the study.  
 Rationale for Sample Size and Statistical Power  
Power analyses and sample size calculation was performed with respect to the first specific aim 
of the primary objective: comparing PI[INVESTIGATOR_268534] -reported 
overdose risk behaviors at 180 days. This was conducted via simu lation. The simulations required 
specifying the data generating/simulation process and a hypothesis test.  
The self -reported overdose risk behaviors to be used for this trial are modified and expanded form 
one used by [CONTACT_268619], et al (2016) [23]. In their version, the maximum score was 32 and they 
found an average of 3.3 and 3.8 in their control and intervention groups, respectively, at baseline . 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326825] was a 0.72 rate ratio (RR). To this end, for the power simulations presented 
here, a mean of 3.[ADDRESS_326826] of 0.72.  For each (simulated) 
participant, a baseline score was generated from a Poisson distribution with a mean, or 𝜆 value, 
of 3.55. As a Poisson regression model with covariates for baseline score, treatment, site, and 
stratum will be used for power simulatio n purposes, coefficients for each must be specified for the 
simulation. The coefficients for site and stratum were set to [ADDRESS_326827] of either. 
Bohnert, et al (2016) reported a coefficient of approximately 0.068, ln(1.07), for the baseline score 
coefficient, which will also be used here. The intercept was set as approximately 1.03, from setting 
ln(𝜆)=𝛽0+ln(1.07)×𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  and solving for 𝛽0 (assuming both 𝜆 and 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  are 3.55 to 
match the TAU case). The post -treatment outcome value for those assigned to TAU was 
generated from a Poisson distribution with a mean of exp(1.03+ln(1.07)×𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 ), where 
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  was their generated baseline score. For participants assigned to PI[INVESTIGATOR_8571], their post -
treatment outcome value was generated from a Poisson distribution with a mean of 
exp(1.03+ln(1.07)×𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 +ln(0.72)), to achieve the desired 0.72 RR for the same baseline 
values. Site (3 levels) and stratum (2 levels) were also generated for each participant but, again, 
had no effect on the outcome.  
After data was simulated, a Poisson regression model was fit with fixed effects for baseline score, 
treatment, site, and strata. Treatment was declared significant if the p -value for the treatment 
coefficient was strictly less than 0.05. The entire process  was repeated 10,[ADDRESS_326828] of the 3.55 mean at baseline. Given that this trial will use an expanded version 
of the risk behaviors used in Bohnert, et al (2016), it would be reasonable to guess that the mean 
frequency at baseline for this trial would higher. However, a higher value actually (as will be 
shown) increases po wer, so the 3.55 mean used here can be viewed as conservative. Larger 
values of 5, 10, 15, 20, 25 were also used to clearly show this pattern. Also considered were 
different values of the RR: 0.70, 0.74, 0.76, 0.78, and 0.80. Note that values closer to [ADDRESS_326829] lower power with all other settings fixed.  
Results are presented in the table and two figures below. With a mean of 3.55 at baseline and a 
RR of 3.55, there is over 90% power to detect the difference with a sample size of 150. There is 
over 80% power with a lower sample size of 100 as well. Power i ncreases as the mean at baseline 
increases, as shown by [CONTACT_50489] 2 and the Power Results by [CONTACT_268620]. At a mean at 
baseline of as low as 2.8, there is still over 85% power to detect a RR of 0.72 with a sample size 
of 150. Power also increased a s the RR decreased. With a sample size of 150 and a mean at 
baseline of 3.55, there is over 80% power to detect a difference of up to 0.76. The initial estimate 
of a 0.72 RR by [CONTACT_268619], et al (2016) came from data on participants who possibly didn’t 
experi ence an overdose. Their estimate of RR in just the group experiencing an overdose was 
0.65. Their intervention also consisted of just a [ADDRESS_326830] (RR), there 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
52 is reason to believe the value of 0.72 used is conservative. For these reasons (greater than 90% 
power at specified parameters, relative robustness to their specification), a sample size of 150 is 
justified for this trial.  
 Table 2: Power Results  
 Total Sample Size  
Mean Score at Baseline  Rate Ratio  100 125 150 
2.8 0.70 75.99%  85.48%  91.00%  
0.72 69.31%  79.20%  86.92%  
0.74 63.02%  73.39%  80.73%  
0.76 54.99%  65.55%  74.58%  
0.78 47.62%  57.87%  66.25%  
0.80 40.90%  49.40%  56.61%  
3.3 0.70 82.99%  90.65%  95.14%  
0.72 76.74%  85.59%  91.56%  
0.74 70.58%  80.35%  86.68%  
0.76 62.24%  72.37%  80.79%  
0.78 54.51%  65.21%  73.33%  
0.80 46.46%  56.24%  63.67%  
3.55 0.70 85.48%  92.75%  96.15%  
0.72 80.08%  88.34%  93.32%  
0.74 73.70%  82.60%  89.23%  
0.76 65.15%  76.12%  83.57%  
0.78 58.49%  67.16%  76.19%  
0.80 49.38%  59.03%  67.69%  
3.8 0.70 88.40%  93.99%  97.42%  
0.72 82.30%  90.18%  94.83%  
0.74 76.37%  85.09%  90.98%  
0.76 68.74%  78.61%  85.65%  
0.78 60.08%  71.62%  78.76%  
0.80 52.01%  61.83%  69.92%  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
53  Total Sample Size  
Mean Score at Baseline  Rate Ratio  100 125 150 
4.3 0.70 91.46%  96.19%  98.46%  
0.72 86.85%  93.33%  96.79%  
0.74 81.08%  89.28%  93.58%  
0.76 73.69%  83.15%  89.91%  
0.78 65.87%  75.77%  83.44%  
0.80 57.54%  67.32%  75.98%  
Figure 3: Power Results by [CONTACT_268621] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
54 Figure  4: Power Results by [CONTACT_268622]. This was chosen based on preliminarily - 
identified sites  that had peer -led ED programs already instituted .  
 Projected Number of Participants per Site  
This study will enroll a total of approximately [ADDRESS_326831] is included to account for correlation within 
each participant. The template S AS code to fit this model is given below.  
pproc glimmix data = data;  
 class site days participant;  
 model risks = baseline trt|days site strat / dist = poisson link = log;  
 random intercept / subject = participant;  
run; 

NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
55  
where data is the dataset, risks is the outcome, baseline  is the participants risk behavior score at 
baseline, trt is a treatment indicator with a value of 1 indicating PI[INVESTIGATOR_268535] 0 indicating TAU, days  
is the day number of the visit , and site and strat are variables corresponding to the participant’s 
site and stratum level respectively.  
The treatment effect of PI[INVESTIGATOR_268536] a rate ratio (RR; as the exponential 
of the treatment and days interaction at [ADDRESS_326832] of treatment) along with 
95% confidence interval. This can be interpreted, conditionally, as a ratio of the mean risk 
behaviors for those assigned to PI[INVESTIGATOR_268537] 180 days, while all other v ariables (specifically including the baseline value) are the same. 
A value of [ADDRESS_326833] achieved 0 steps at baseline. Similar to 
the primary outcome, a RR alo ng with 95% confidence interval and p -value will be given from this 
model to determine the effec t and significance of PI[INVESTIGATOR_268419].  
An important point to consider is that participants entering the trial may not have a primary 
diagnosis of OUD, or even SUD. Because of this, some steps are not inherently eligible to them 
at baseline. However, during the study, the participant may endorse  OUD, or some SUD if none 
were at baseline, and become eligible for these steps. The approach taken here for the 
prespecified analysis method is that of protection/balanced by [CONTACT_17628]. Participants 
entering without OUD, or no SUD, are likely to be  balanced between treatment groups  due to 
random assignment to treatment group  (based on baseline DSM -5 SUD diagnoses) , such that 
the effects of this would be equal between PI[INVESTIGATOR_268538]. Additional supportive analyses, 
such as looking at OUD, SUD other than OUD, and no SUD subgroups as determined at baseline, 
are possible to examine possible chance imbalance between PI [INVESTIGATOR_268538].  
For the other secondary outcome s, the number of participants approached and number who were 
willing to engage with CPPSs using the PI[INVESTIGATOR_268404], as well as percent of those approached 
who were willing to engage, will be summarized. A 95% confidence interval will be provided for 
this percent.  The length of engagement with PI[INVESTIGATOR_268539].  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326834] with a type I error rate of 0.05, or 
5%. The same procedure will be used for the key secondary hypothesis  and the secondary 
outcome of number of steps achieved on the modified SUD cascade of care . No attempt will be 
made to adjust for multiple testing  on the secondary outcomes  as inference is focused on the 
single primary outcome hypothesis test.  
The exploratory objectives will be tested as applicable, with a two-sided  test and with a type I 
error rate of 0.05. No attempt will be made to adjust for multiple comparisons within the exploratory 
objectives.  
 Sensitivity and other Supportive Analyses  
It will be helpful to characterize the distribution , and other characteristics , of the primary outcome  
to assist in planning future studies . Therefore, a model building process will be performed. Various 
count response regression models will be considered, including but not limited to:  
• Poisson regression, with or without overdispersion  
• Negative Binomial regression, with or without overdispersion  
• Zero inflated Poisson regression  
• Zero inflated Negative Binomial regression  
The reasoning for including the Negative Binomial distribution -based regression is that it can 
account for over/under dispersion more directly than Poisson regression because it has a second 
parameter, as opposed to the Poisson distribution that is entirel y specified by [CONTACT_268623]. Zero 
inflated versions of these are also considered because it is possible that a proportion of the 
participants will have a score of  zero that is not in line with that specified by [CONTACT_268624]. A normal distribution may also be considered if the outcome 
appears to fit.   
Whichever model is finally chosen for the outcome, based on model fitting quality (including 
deviance) and/or BIC, the effect of treatment will be assessed with a n appropriate (for that model)  
two-sided  test with a type I error rate of 0.05. In the models listed above without zero inflation, the 
treatment effect is measured as a RR from the model. In models with zero inflation, the role of 
treatment in the proportion of zeros will be summarized, along wi th an RR. Site will be included in 
the models as well as a random effect to assess the variability in the outcome due to site and to 
estimate the site effect standard deviation which also may be useful for future trials.  
If changes to recruitment are made because of slow enrollment from EDs, an additional covariate 
indicating whether a participant was enrolled was initially defined from EDs, or otherwise, may be 
included to examine its effect on the outcomes.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326835] of PI[INVESTIGATOR_268540] (OR). The 
OR will be reported, along with 95% confidence interval and p -value, will be reported for 
each step. This process will be repeated for the [ADDRESS_326836] of PI[INVESTIGATOR_268541] 95% confidence interval. A Chi -
squared test will be performed.  
3. Number of days of self -reported frequency of use in the past [ADDRESS_326837] will be 
measured by a RR with 95% confidence interval. A hypothesis test analogous to the 
primary outcome will be conducted.  
5. Self-reported attendance in a [ADDRESS_326838] o f 
PI[INVESTIGATOR_268542] 95% confidence interval. A 
Chi-squared test will be performed.  
6. The percent of toxicology screens positive for primary substance of use will be 
summarized by [CONTACT_268625] 0%, mean, median, standard deviation, range 
(including minimum and maximum), and IQR (including 25th and 75th percentiles) by 
[CONTACT_19480] m.  
7. Occurrence of a non -fatal overdose at any time during study participations will be 
summarized by [CONTACT_22977]. The effect of PI[INVESTIGATOR_268543] 95% confidence interval. A Chi -squared test will be 
performe d. The same process will be done for all -cause mortality and death by 
[CONTACT_268582]. In the event of likely dropout, time -to-event analyses may need to be 
performed instead. In such cases, simple Kaplan -Meier plots will be given with 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326839] of PI[INVESTIGATOR_268419]. Cox proportional 
hazards regression models may be considered as well. All -cause mortality or death by 
[CONTACT_268626] a competing risk for non -fatal overdose. Causes of death differe nt 
from overdose (that is, those with an all -cause mortality that aren’t overdose) may 
present a competing risk for death by [CONTACT_268627]. As such, appropriate Fine and 
Gray models need be considered.  
 Missing Data and Dropouts  
The prespecified primary outcome analysis method takes into account all available data so that 
special provisions are not needed for missing data. However, missing data handling methods, 
such as multiple imputation, may be considered as possible sensitivit y analyses.  
By [CONTACT_108], the secondary outcome of number of steps achieved on the modified SUD cascade 
of care will have no missing data. Either evidence was previously obtained that a step was 
achieved,  or evidence was never collected that the step was achieved (and thus wasn’t achieved).  
 Demographic and Baseline Characteristics  
Baseline demographic and clinical variables will be summarized for participants enrolled in the 
active intervention phase of the trial. Descriptive summaries of the distribution of continuous 
baseline variables will be presented with percentiles (median, 2 5th and 75th percentiles), and with 
mean and standard deviation. Categorical variables will be summarized in terms of frequencies 
and percentages.  
 Subgroup Analyses  
Per NIH policy, subgroup analys es will be implemented to assess whether sex, race, and/or 
ethnicity are feasibility or effect modifiers. The primary outcome  results will be presented and 
tested (as applicable) within each demographic subgroup  by [CONTACT_268628] . 
 Safety Analysis  
The study’s targeted safety events (ED visits, hospi[INVESTIGATOR_602], non -fatal overdoses, and suicidal 
ideation) will be summarized in tabular form.  A listing of death events will include  the following: 
system organ class (SOC) and preferred term (PT) using Medical Dictionary for Regulatory 
Activities (MedDRA) codes ; primary and secondary cause s of death ; and whether the death had 
drug or alcohol -related contributing factors (even if not listed as primary cause of death) . 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
59 
 REGULATORY COMPLIANCE AND SAFETY  
 Statement of Compliance  
This trial will be conducted in accordance with the current version of the protocol, in full conformity  
with the ethical principles outlined in the Declaration of Helsinki, the Protection of Human Subjects 
described in the International Council for  Harmoni zation  Good Clinical Practice (GCP) Guidelines,  
applicable [LOCATION_002] (US) Code of Federal Regulations (CFR), the NIDA Terms and 
Conditions of Award,  and all other applicable state, local, and federal regulatory requirements. 
The Principal Investigator [INVESTIGATOR_175249] n o deviation from, or changes to  the protocol will take 
place without prior agreement from the Sponsor  and documented approval from the Institutional 
Review Board ( IRB), except where necessary to eliminate an immediate hazard(s) to the trial 
participants. An Operations Manual will be provided as a reference guide and study quality 
assurance tool.  
 Institutional Review Board Approval  
Prior to initiating the study, participating site investigators will obtain written approval from the ir 
Institutional Review Board (IRB)  to conduct the study at their respective site , and reliance 
agreements will be initiated and executed for a single IRB for this study. The MUSC IRB will serve 
as the IRB of record for this multi -site study. If changes to the study protocol become necessary, 
protocol amendments will be submitted in writing by [CONTACT_9905]. In ad dition, IRBs will approve all consent forms, recruitment materials  and 
procedures , and any materials given to the participant , and any changes made to these 
documents throughout study implementation . Approval of both the protocol and the consent 
form(s) must be obtained before any participant is consented.  For changes to the consent form, 
a decision will be made regarding whether previously consented participants need to be re -
consented.  IRB continuing review will be performed  annually , or at a greater frequency contingent 
upon the complexity and risk of the study . Each  site principal  investigator [INVESTIGATOR_268544], IRB -approved consent documents,  and 
approval for all protocol modifications. These materials must be received by [CONTACT_268629].  
Unanticipated problems involving risk to study participants will be promptly reported to and 
reviewed by [CONTACT_268630] , according to its usual procedures.  
MUSC IRB  will be the IRB of record for the protocol and will provide study oversight in accordance 
with [ADDRESS_326840] entered 
into reliance/authorization agreements for Protocol CTN -0107. MUSC IRB  will follow written 
procedures for reporting its findings and actions to appropriate officials at each participating 
institution. Some sites may meet Exception Criteria to the NIH sIRB Policy and may not utilize the 
IRB of Record.  
 Informed Consent  
The informed consent process is a means of providing study information to each prospective 
participant and allows for an informed decision about participation in the study.  Informed consent 
continues throughout the individual’s study participation.  The informed consent form (s) will include 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326841] the study 
informed consent (s) approved by [CONTACT_268631] . Prior to initial submission to the IRB and with 
each subsequent consent revision, the consent form(s) must be sent to the Clinical Coordinating 
Center (CCC) and the Lead Node (LN) to confirm that each consent form contains the required 
elements of informed  consent as delineated in 21 CFR 50.25(a) and CFR 46.116(b), as well as 
pertinent additional elements detailed in 21 CFR 50.25(b) and 45 CFR 46.116(c) and any 
applicable CCTN requirements. Every study participant is required to sign a valid, IRB -approved 
current version of the study informed consent form prior to the initiation of any study related 
procedures. The site must maintain the original signed informed consent for every participant in 
a locked, secure location that complies  with all applicable  IRB and institutional policies  and that 
is accessible to the study monitors. Every study participant should be given a copy of the signed 
consent form.  As a back -up method to in -person informed consent procedures, study sites will 
use REDCap eConsent, if in person consent is not possible for a particular participant.  
During the  informed consent  process , research staff will explain the study to the potential 
participant and provide  the potential participant with  a copy of the consent form to read  and keep 
for reference . All participants will receive a verbal explanation in terms suited to their 
comprehension of the purposes, procedures, and potential risks of the study and their rights as 
research participants. Extensive discussion of risks and possible benefits will be provided to the 
participants.  Participants will have the opportunity to carefully review the written consent form and 
ask questions p rior to signing. The participants should have the opportunity to discuss the study 
with their family and close friends or think about it prior to agreeing to participate. If the participant 
is interested in participating in the study, a qualified staff member will review each section of the 
IRB-approved informed consent form in detail and answer any questions the participant may 
pose. The participant , or participant’s legally authorized representative,  will consent by [CONTACT_268632] . The person obtaining consent and a witness, if required by [CONTACT_268633] , will also sign and date the consent document. It is strongly recommended that 
another research staff member review the consent after it is signed to ensure that the consent is 
properly executed and complete. Staff members delegated by [CONTACT_978] [INVESTIGATOR_268545], if required. All persons obtaining consent must have co mpleted appropriate  GCP and 
Human Subjects Protection  training , as mandated by [CONTACT_268634] . 
As a backup method, REDCap electronic consent (e -consent) , combined with a HIPAA -secure 
video  conferencing platform , will be used  during the consent process (preferred). Participants are 
also able to view  the informed consent document on a computer or phone via REDCap and 
complete a phone call with research staff. Video chat functionality will only be used if all parties 
have the availability and is not required for consent to be performed. Approved research staff 
members will have an MUSC external NetID, w hich allows them to access MUSC’s version of 
REDCap. Each study site will have their own MUSC REDCap eConsent database managed by 
[CONTACT_268635] . Using these 
systems, signatures on the consent form may be obtained electronically via REDCap.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326842] participants’ 
participation in the trial. The rights and welfare of the participants will be protected by [CONTACT_200876].  The participant will be informed that their participation is voluntary,  and 
they may withdraw from t he study at any time, for any reason without penalty. Individuals who 
refuse to participate or who withdraw from the study will be treated without prejudice. Study sites 
will be responsible for maintaining signed consent forms as source documents for quali ty 
assurance review and regulatory compliance.  
 Quality Assurance Monitoring  
In accordance with federal regulations, the study sponsor is responsible for ensuring proper 
monitoring of an investigation and ensuring that the investigation is conducted in accordance with 
the protocol. Qualified monitors will oversee aspects of site co nformity to make certain the site 
staff is operating within the confines of the protocol, and in accordance with GCP. This includes 
but is not limited to protocol compliance, documentation auditing, and ensuring the informed 
consent process is being correc tly followed and documented. Non -conformity with protocol and 
federal regulations will be reported as a protocol deviation and submitted to the study sponsor 
and study IRB of record, (as applicable), for further review.  
Investigators will host periodic visits by [CONTACT_268636], site and study SOPs are followed, and that study data are generated,  
documented , and reported in compliance with the protocol, GCP, and applicable regulations.  
These monitors will audit, at mutually agreed upon times, regulatory documents, CRFs, and  
corresponding source documents for each participant. Monitors will have the opportunity and  
ability to review any study -associated document or file.  
NIDA -contracted monitors will assess whether submitted data are accurate and in agreement with  
source documentation and will also review regulatory/essential documents such as  
correspondence with the IRB. Areas of particular concern will be participant informed consent  
forms, protocol adherence, reported safety events and corresponding assessments, and PI  
[INVESTIGATOR_200762]. Reports will be prepared following the visit and forwarded  
to the site PI, the Lead Investigator (LI), and NIDA Ce nter for Clinical Trials Network (CCTN).  
Qualified node personnel (Node Protocol Managers and/or Quality Assurance (QA) monitors) or  
other designated party(ies) will provide site management for each site during the trial. Node QA  
personnel or other designated party(ies) will audit source documentation, including informed  
consent forms and HIPAA forms. This will take place as specified by [CONTACT_9920], node  
PI [INVESTIGATOR_268546], detect, and correct problems  
at the study sites. Node QA personne l will verify that study procedures are properly followed and  
that site staffs are trained and able to conduct the protocol appropriately. If the node staff’s review  
of study documentation indicates that additional training of study personnel is needed, node staff  
will undertake or arrange for that training. Details of the contract, node QA and data monitoring  
are found in the study QA monitoring plan.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326843] by [CONTACT_3486], 
their staff, the safety and oversight monitor(s), and the sponsor(s) and funding agency , and will 
be maintained in accordance with all applicable federal regulations and/or state/Commonwealth 
law and regulations.  This confidentiality is extended to the data being collected as part of this 
study. Data that could be used to identify a specific study participant will be held in strict 
confidence within the re search team , unless  such disclosures are required by [CONTACT_7720] , when the 
study clinician  is not readily available , there is concern that urgent clinical assessment is needed 
to protect the participant’s  personal safety or welfare . In these cases , researchers may need to 
disclose medical and health -related research data to authorities and/or non-study care providers . 
Other than these  exception s, no personally  identifiable information from the study will be released 
to any unauthorized third party without prior written approval of the sponsor/funding agency  and 
the participant .  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor or funding agency, 
representatives of the Institutional Review Board (IRB), regulatory agencies or representatives 
from companies or organizations supplying the product, may inspect all documents and records 
required to be maintained by [CONTACT_093], including but not limited to, medical records (office, 
clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for  the participants in this study. The clinical study site 
will permit access to such records.  
Participant records will be held confidential using  study codes for identifying participants on CRFs, 
secure storage of any documents that have participant identifiers, and secure computing 
procedures for entering and transferring electronic data.  The study participant’s contact 
[CONTACT_10414]. At the end 
of the study, all records will continue to be kept in a secure location for as long a period as  denoted 
in Section 15.11, Record s Retention and Requirements .  
By [CONTACT_200877] , the investigator affirms that information furnished to the 
investigator by [CONTACT_200878]/Privacy Board, Ethical Review Committee, or similar expert committee , and/or to  the affiliated 
institution and its employees , only under an appropriate understanding of confidentiality with such 
board or committee, and/or affiliated institution and its employees.  
 Certificate of Confidentiality  
To further protect the privacy of study participants, the Secretary, Health and Human Services 
(HHS), has issued a Certificate of Confidentiality (CoC) to all researchers engaged in biomedical, 
behavioral, clinical , or other human subjects research funded wholly or in part by [CONTACT_200879].  Recipi[INVESTIGATOR_200760] (see 
https://humansubjects.nih.gov/coc/index ). This protects participants from disclosure of sensitive 
information (e.g., drug use).  It is the NIH policy that investigators and others who have access to 
research records will not disclose identifying information except when the participant consents  or 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326844] (HIPAA)  
Study sites may be required by [CONTACT_268637]. Sites will be responsible for communicating with their IRBs or 
Privacy Boards and obtaining the appropriate approvals or wa ivers to be in regulatory compliance. 
Releases of participant identifying information that are permitted by [CONTACT_9911], but 
which are prohibited by [CONTACT_9912]/or state/Commonwealth law and 
regulation, are prohibited . 
 Investigator Assurances  
Each site must have on file a n active  Federal wide Assurance (FWA) with the HHS Office for 
Human Research Protection setting forth the commitment of the organization to establish 
appropriate policies and procedures for the protection of human research subjects  in alignment 
with 45 CFR 46, Subpart A , with documentation sent to NIDA or its designee. Research covered 
by [CONTACT_268638] I RB provided for in the assurance (45 CFR 
46.103). Prior to initiating the study, the principal investigator [INVESTIGATOR_200761] a protocol 
signature [CONTACT_268658] , providing assurances that the study will be performed 
according to the standards stipulated therein . 
 Financial Disclosure /Conflict of Interest  
All investigators will comply with the requirements of [ADDRESS_326845] monitors who will examine whether study 
procedures are conducted appropriately,  and that study data are generated, documented , and 
reported in compliance with the protocol, GCP, and applicable regulations. These monitors will 
audit, at mutually agreed upon times, regulatory documents, case report forms (CRFs), informed 
consent forms and corresponding source documents for each par ticipant. Monitors will have the 
opportunity and ability to review any study -associated document or file.  
NIDA -contracted monitors will assess whether submitted data are accurate and in agreement with 
source documentation and will also review regulatory/essential documents such as 
correspondence with the IRB. Areas of particular concern will be participant inf ormed consent 
forms, protocol adherence, reported safety events and corresponding assessments, and principal 
investigator [INVESTIGATOR_200762]. Reports will be prepared following the visit and 
forwarded to the site principal investigator,  the lead investigator and NIDA CCTN.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
64 Qualified node personnel (Node QA monitors)  or other designated party(ies)  will provide site 
management for each site during the trial. Node QA staff or other designated party(ies) will audit 
source documentation, including informed consent forms and HIPAA forms. This will take place 
as specified by [CONTACT_9920], node PI [INVESTIGATOR_200763], detect, and correct problems at the stu dy sites. Node QA personnel will verify 
that study procedures are properly followed and that site personnel are trained and able to 
conduct the protocol appropriately. If the node personnel’s review of study documentation 
indicates that additional training of site study personnel is needed, node QA personnel will 
undertake or arr ange for that training. Details of the contract, node QA and data monitoring are 
found in the study QA monitoring plan.  
 Inclusion of Women and Minorities  
The study sites should aim and take steps to enroll  a diverse study population. The rates of 
women and minorities enrolled will depend on sites selected to participate and their ED 
admissions of NFOO. The study will aim to enroll 30 -40% women in the trial and 20 -25% racial 
and ethnic minorities. If difficulty is encountered in recruiting an adequate number of women 
and/or minorities, the difficulties involved in recruitment will be discussed in national conference 
calls and/or face -to-face meetings, encoura ging such strategies as linkages with medical sites 
and or treatment programs that serve a large number of women and/or minorities, advertising in 
newspapers or radio stations with a high female/minority readership/listening audience, etc.  
 Prisoner Certification  
As per 45 CFR 46 Subpart C, there are additional protections pertaining to prisoners as study 
participants. A prisoner is defined as any individual involuntarily confined or detained in a penal 
institution. The term is intended to encompass individuals sentenced to such an institution under 
a criminal or civil statute, individuals detained in other facilities by [CONTACT_268639] a penal 
institution, and individ uals detained pending arraignment, trial, or sentencing.  To meet these 
additional protections, the study team will obtain certification from the Office for Human Research 
Protections (OHRP) to follow -up with participants who become prisoners during the study, as 
necessary.   
Participants in this study will be individuals with a history of substance use, misuse, and opi[INVESTIGATOR_2480] -
related overdose. Participants may be at a greater risk of becoming involved with the criminal 
justice system. In accordance with exclusion criterion #4 [“Cu rrently in jail, prison or in police 
custody at the time of the index ED visit or under current terms of civil commitment or guardianship 
(i.e., OHRP -defined prisoner status)”], this study will not enroll participants currently involved with 
the criminal j ustice system. However, there is a chance that during the study, a participant could 
become incarcerated or otherwise meet the definition of a prisoner (as delineated in 45 CFR 
46.303(c)). Those participants who become incarcerated during their involvement  with this study 
will continue to be followed to ensure safety and data integrity (following OHRP approval and with 
compliance to local state and country rules and restrictions).  
Prisoner  contact [CONTACT_21401] : All study sites will follow the same guidelines surrounding contact 
[CONTACT_268640]. Detailed local SOPs will be developed by 
[CONTACT_268589] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326846]. All sites will follow these general 
guidelines: 1) the site (inclusive of RA/RCs and PI[INVESTIGATOR_268448] , when applicable ) will not contact 
[CONTACT_268641] (obtained following informed 
consent with a release of informa tion and agreement to be contact[CONTACT_268642]), 2) the study site (inclusive of RA/RCs and PI[INVESTIGATOR_268421]) may also use IRB-
approved language  that can be sent to the detention facility  requesting permission to contact [CONTACT_268643] a time for a follow -up research study visit and visit from the PI[INVESTIGATOR_268547] 
(as applicable) , 3) study participants will not be compensated for completing study procedures 
while they are incarcerated. If permitted by [CONTACT_54443]/local regulations , the s ite may defer 
compensation for study procedures  completed while the participant is incarcerated until the 
participant is no longer considered a prisoner (see local SOPs for site -specific details and 
procedures for deferred compensation) , 4) if a study participant becomes incarcerated, study staff 
(inclusive of RA/RCs and PI[INVESTIGATOR_268421]) must adhere to  local restrictions at that particular facility  
regarding contact [CONTACT_268644] , 5) in-person visits, telephone calls, video chat, etc. 
will be allow ed to maintain rapport and/or collect study visit data . Contact [CONTACT_268645]-secured lines  and/or in monitored rooms  being mindful of sensitive information 
and safety. Any r esearch data collection must  only be obtained through secure means ( e.g., in a 
private room  where  not being recorded  and/or  on a secure line, etc.).  
 Regulatory Files  
The regulatory files should contain all required regulatory documents, study -specific documents, 
and important communications. Regulatory files will be checked at each participating site for 
regulatory document compliance prior to study initiation, throughout the study, as well as at study 
closure.  
 Records Retention and Requirements  
Research records for all study participants (e.g., case report forms, source documents, signed 
consent forms,  audio and video recordings  [if applicable] , and regulatory files) are to be 
maintained by [CONTACT_9916] a secure location for a minimum of [ADDRESS_326847] or outcome of the trial or increase risk to study participants. Safety 
reporting will occur as previously described. At the completion of the trial, the Lead Investigator 
will provide a final report to the Sponsor.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
66 
 Audits  
The Sponsor has an obligation to ensure that this trial is conducted according to good clinical 
research practice guidelines and may perform quality assurance audits for protocol compliance. 
The Lead Investigator and authorized staff from the Southern Consortium Node ; the National 
Institute on Drug Abuse Clinical Trials Network (NIDA CTN, the study sponsor); NIDA’s contracted 
agents, monitors or auditors; and other agencies such as the Department of Health and Human 
Services (HHS), the Office for Human Rese arch Protection (OHRP) and the Institutional Review 
Board of record may inspect research records for verification of data, compliance with federal 
guidelines on human participant research, and to assess participant safety.  
 Study Documentation  
Each participating site will maintain appropriate study documentation (including medical and 
research records) for this trial, in compliance with ICH E6 R2 and regulatory and institutional 
requirements for the protection of confidentiality of participants.  Study documentation includes all 
case report forms, workbooks, source documents, monitoring logs and appointment schedules, 
sponsor -investigator correspondence, and signed protocol and amendments, Ethics Review 
Committee or Institutional Review Committee correspondence and approved consent form and 
signed participant consent forms.  As part of participating in a NIDA -sponsored study, each site 
will permit authorized representatives from NIDA and regulatory agencies to examine (and when 
permitted by [CONTACT_2371], to copy) clinical records for the purposes of quality assurance reviews, audits, 
and evaluation of the study safety, progress, and data validity.  
Source documents include all recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical research study. 
Whenever possible, the original recording of an observation should be retained as th e source 
document; however, a photocopy is acceptable if it is a clear, legible, and exact duplication of the 
original document.  
 Protocol Deviations  
This protocol defines a protocol deviation as any noncompliance w ith the clinical trial protocol . 
The noncompliance may be either on the part of the participant, the investigator, or the study site 
staff. As a result of deviations, corrective actions will be developed by [CONTACT_48162].  
These practices are consistent with ICH GCP:  
• Section 4.5 Compliance with Protocol, subsections 4.5.1, 4.5.2, and 4.5.3  
• Section 5.1 Quality Assurance and Quality Control, subsection 5.1.1  
• Section 5.20 Noncompliance, subsections 5.20.1, and 5.20.2.  
Any departure from procedures and requirements outlined in the protocol will be classified as 
either a major or minor protocol deviation. The difference between a major and minor protocol 
deviation has to do with the seriousness of the event and the correc tive action required. A minor 
protocol deviation is considered an action (or inaction) that by [CONTACT_268646] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326848] the safety, rights, or welfare of a study 
participant. Major protocol deviations are departures that may compromise the participant safety, 
participant rights, inclusion/exclusion criteria or th e integrity of study data and could be cause for 
corrective actions if not rectified or prevented from re -occurrence. Sites will be responsible for 
developi[INVESTIGATOR_9818]. Those 
corrective acti on plans may be reviewed/approved by [CONTACT_268647] . All protocol deviations will be monitored at each site for 
(1) significance, (2) frequency, and (3) impact on the study objectives, to ensure that site 
performance does not compromise the integrity of the trial.  
All protocol deviations will be recorded in the Electronic Data Capture (EDC) system via the 
Protocol Deviation CRF. The CCC, DSC and the Lead Investigator must be contact[CONTACT_268648]. 
Additionally, each site is responsible for reviewing their local IRB’s definition of a protocol 
deviation or violation and understanding which events need to be reported. Sites must recognize 
that the CTN and IRB definition of a reportable event may differ  and act accordingly in following 
all reporting requirements for both entities.  
 Safety Monitoring  
Given the low -risk nature of the PI[INVESTIGATOR_268548], only select Adverse Events 
(AEs) and Serious Adverse Events ( SAEs ), collectively termed Safety Events  will be tracked and 
reported during this study. Accordingly, Safety Events associated with participant  death, post -
index overdoses, ED visits, and hospi[INVESTIGATOR_268549] 30 -, 90-, 180 -, and 
210-day visits (or in -between visits if reported spontaneously). Other AEs and SAEs will not be 
solicited, documented, or reported in the data system during this protocol. Reporting timeframes 
for Safety Events will follow regulatory requirements.  While active su icidal ideation at the 
screening visit is considered an exclusion criterion, participant suicidal ideation occurring after 
enrollment will be addressed in accordance with Section 11.7.1 . 
The Lead Investigator (LI) and Site PI [INVESTIGATOR_268550]. These reviews will include an assessment of the possible relatedness of the event to 
the study intervention or other study procedures. The Site  PI [INVESTIGATOR_268551], refer, or withdraw participants as required. In addition, NIDA will assign a Safety 
Monitor/Medical Monitor to this protocol to independently review the safety data, present it to the 
DSMB for periodic  review, and provide PIs a Safety Letter when necessary. The Safety 
Monitor/Medical Monitor will determine which Safety Events require expedited reporting to NIDA, 
the DSMB and regulatory authorities. This will include events that are serious, related , and 
unexpected. The study staff will be trained to monitor for and report Safety Events . 
Each of the sites has established practices for managing medical and psychiatric emergencies, 
and the study staff will continue to utilize these procedures. Treatment providers at each site will 
be responsible for monitoring participants for possible clinical deterioration or other problems, and 
for implementing appropriate courses of action.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326849] (DSMB)  
An independent CTN DSMB will examine accumulating data to assure protection of participants’ 
safety while the study’s scientific goals are being met. The CTN DSMB is responsible for 
conducting periodic reviews of accumulating safety and efficacy data. It w ill determine whether 
there is support for continuation of the trial, or evidence that study procedures should be changed, 
or if the trial should be halted, for reasons relating to the safety of the study participants, the 
efficacy of the treatment under s tudy, or inadequate trial performance (e.g., poor recruitment).  
 Safety Monitor/Medical Monitor  
The CCC Safety Monitor/Medical Monitor is responsible for reviewing all Safety Events  reported. 
Where further information is needed , the Safety Monitor/Medical Monitor will discuss the Safety 
Event with the site. Reviews of Safety Events will be conducted in the Advantage  eClinical  data 
system and will be a part of the safety database. A ll Safety Events will be  reviewed on a regular  
basis to observe trends or unusual events.  
The CCC Safety Monitor/Medical Monitor will in turn report Safety E vents to the sponsor and 
regulatory authorities if the event meets the definition of an expedited event. Reports will be 
generated and presented for Data Safety Monitoring Board (DSMB) meetings.  
 Safety Events  
For the purposes of this protocol, the collection and reporting of  the following  Safety E vents  are 
not required in the data system : 
• Pregnancy  
• Admission for detoxification  
• Elective hospi[INVESTIGATOR_268552] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
69 
 DATA MANAGEMENT  
 Design and Development  
This protocol will utilize a centralized Data and Statistics Center (DSC). The DSC will be 
responsible for development of the electronic case report forms (eCRFs), development and 
validation of the clinical study database, ensuring data integrity, and trai ning site and participating 
node staff on applicable data management procedures. Advantage eClinical , QualtricsXM, and 
REDCap  entry systems will be implemented. These systems will be developed to ensure that 
guidelines and regulations surrounding the use o f computerized systems used in clinical trials are 
upheld. Advantage eClinical will be developed by [CONTACT_268649] . The QualtricsXM system will be used 
by [CONTACT_268650].  The REDCap system will be developed and managed by [CONTACT_268651], which will be used for participants to complete their weekly surveys . The remainder 
of this section provides an overview of the data management plan associated with this protocol.  
The DSC will receive the  REDCap weekly survey  data regularly throughout the trial, will conduct 
data quality activities (to the extent feasible on participant entered data), and will be responsible 
for data analysis.  For the REDCap TAU Characterization and Peer Surveys, the DSC will receive 
this de -identified data only at the end of the trial due to the limited nature of confidentiality possible 
on these assessments, and DSC will not be responsible for analyzing these data.  
 Site Responsibilities  
The data management responsibilities of each individual site will be specified by [CONTACT_268652] a User’s Guide.  
 Data Center Responsibilities  
The DSC will 1) develop a data management plan and will conduct data management activities 
in accordance with that plan, 2) provide final guided source documents and eCRFs for the 
collection of all data required by [CONTACT_1758], 3) develop data dictionaries f or each eCRF that will 
comprehensively define each data element, 4) conduct ongoing data monitoring activities on 
study data from all participating sites, 5) monitor any preliminary analysis data cleaning activities 
as needed, and 6) rigorously monitor fin al study data cleaning.  
 Data Collection  
The data collection process consists of direct data entry at the study sites into the Advantage 
eClinical Electronic Data Capture systems (EDC). If Advantage eClinical is not available, the DSC 
will provide the sites with a final set of guided source documents and completion instructions. 
Data entry into Advantage eClinical should be completed according to the instructions provided 
and protocol speci fic training. The investigator is responsible for maintaining accurate, complete , 
and up -to-date records, and for ensuring the completion of the eCRFs for each research 
participant.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
70 
 Data Acquisition and Entry  
Completed forms and electronic data will be entered into Advantage eClinical in accordance with 
the User’s Guide. Only authorized individuals shall have access to eCRFs.  
 Data Editing  
Completed data will be entered into Advantage eClinical. If incomplete or inaccurate data are 
found, a query will be generated to the sites for a response , though queries for missing data will 
not be generated for mobile surveys . Site study staff will resolve data inconsistencies and errors 
and enter all corrections and changes into Advantage eClinical.  
 Data Transfer/Lock  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at the DSC. This will not include the participant’s 
contact [CONTACT_1290]. Rather, individual participan ts and their research data will be 
identified by a unique study identification number. The study data entry and study management 
systems used by [CONTACT_268653].  
Data will be transmitted by [CONTACT_268654]. 
The DSC will conduct final data quality assurance checks and “lock” the study database from 
further modification. The final analysis dataset will be returned to N IDA, as requested, for storage 
and archive.  
 Data Training  
The training plan for site staff includes provisions for training on assessments, eCRF completion 
guidelines, data management procedures, and the use of Advantage eClinical  or other applicable 
EDC systems . 
 Data Quality Assurance  
To address the issue of data entry quality, the DSC will follow a standard data monitoring plan. 
An acceptable quality level prior to study lock or closeout will be established as a part of the data 
management plan. Data quality summaries will be made avai lable during the protocol.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
71 
 DATA SHARING, PUBLIC ACCESS , AND PUBLICATIONS  
This study will comply with the NIH Data Sharing Policy and Implementation Guidance 
(https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm ) and the HEAL 
Public Access and Data Sharing Policy ( https://www.nih.gov/research -training/medical -research -
initiatives/heal -initiative/research/heal -public -access -data-sharing -policy ).  
Investigators will also register and report results of the trial in ClinicalTrials.gov, consistent with 
the requirements of the Policy on the Dissemination of NIH -Funded Clinical Trial Information and 
the Clinical Trials Registration ( https://grants.nih.gov/policy/clinical -trials/reporting/  
understanding/nih -policy.htm ). 
Primary data for this study will be available to the public in the NIDA data repository, per NIDA 
CTN policy. An exception to data sharing is for data collected at the site level , which cannot be 
sufficiently de -identified given only three participating sites. Data that characterizes treatment as 
usual for the study site will not be shared on the NIDA data repository.  Additionally, data collected 
to characterize the PI[INVESTIGATOR_268553] s ensitive information and cannot be sufficiently de -identified. For more details on 
data sharing please visit https://datashare.nida.nih.gov/ . 
The primary outcome publication will be included along with study underlying primary data in the 
data share repository, and it will also be deposited in PubMed Central 
http://www.pubmedcentral.nih.gov/  per NIH Policy (http://publicaccess.nih.gov/) . 
The planning, preparation, and submission of publications will follow the policies of the 
Publications Committee of the CTN. Considerations for ensuring confidentiality of any shared data 
are described in Section 15.5. 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
72 
 PROTOCOL SIGNATURE [CONTACT_268659]’S REPRESENTATIVE (CCTN SCIENTIFIC OFFICER OR DESIGNEE)  
     
          
Printed Name   [CONTACT_9944] [CONTACT_9929]:  
• I am in receipt of version 6.[ADDRESS_326850] this clinical study in 
accordance with the design and provisions specified therein.  
• I agree to follow the protocol as written except in cases where necessary to protect the 
safety, rights, or welfare of a participant, an alteration is required, and the sponsor and IRB 
have been notified prior to the action.  
• I will ensure that the requirements relating to obtaining informed consent and institutional 
review board (IRB) review and approval in 45 CFR 46 are met.  
• I agree to personally conduct or supervise this investigation at this site and to ensure that 
all site staff assisting in the conduct of this study are adequately and appropriately trained 
to implement this version of the protocol and that they are qualifi ed to meet the 
responsibilities to which they have been assigned.  
• I agree to comply with all the applicable federal, state, and local regulations regarding the 
obligations of clinical investigators as required by [CONTACT_9930] (DHHS), the state, and the IRB.  
 
SITE’S PRINCIPAL INVESTIGATOR  
          
[INVESTIGATOR_268554] -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
73 
 REFERENCES  
1. Martins, S.S., et al., Worldwide Prevalence and Trends in Unintentional Drug Overdose: 
A Systematic Review of the Literature.  Am J Public Health, 2015. 105(11): p. e29 -49. 
2. Woolf, S.H. and H. Schoomaker, Life Expectancy and Mortality Rates in the [LOCATION_002], 
1959 -2017.  Jama, 2019. 322(20): p. 1996 -2016.  
3. Larochelle, M.R., et al., Medication for Opi[INVESTIGATOR_268555]: A Cohort Study.  Ann Intern Med, 2018. 169(3): 
p. 137 -145. 
4. Weiner, S., et al., One-year mortality of opi[INVESTIGATOR_268556].  Annals of Emergency Medicine, 2017. 70(4): p. S158.  
5. Weiner, S.G., et al., One-Year Mortality of Patients After Emergency Department 
Treatment for Nonfatal Opi[INVESTIGATOR_268557].  Ann Emerg Med, 2020. 75(1): p. 13 -17. 
6. Chen, Y., et al., A systematic review of opi[INVESTIGATOR_268558].  Drug Alcohol Depend, 2020. 213: p. 108009.  
7. McGuire, A.B., et al., Emergency department -based peer support for opi[INVESTIGATOR_2427]: 
Emergent functions and forms.  J Subst Abuse Treat, 2020. 108: p. 82 -87. 
8. D'Onofrio, G., et al., Emergency department -initiated buprenorphine/naloxone treatment 
for opi[INVESTIGATOR_2561]: a randomized clinical trial.  Jama, 2015. 313(16): p. 1636 -44. 
9. Morgan, J.R., et al., Overdose following initiation of naltrexone and buprenorphine 
medication treatment for opi[INVESTIGATOR_268559] a [LOCATION_002] commercially insured 
cohort.  Drug Alcohol Depend, 2019. 200: p. 34 -39. 
10. Sordo, L., et al., Mortality risk during and after opi[INVESTIGATOR_207659]: systematic 
review and meta -analysis of cohort studies.  Bmj, 2017. 357: p. j1550.  
11. Langabeer, J., et al., Outreach to people who survive opi[INVESTIGATOR_46211]: Linkage and 
retention in treatment.  J Subst Abuse Treat, 2020. 111: p. 11 -15. 
12. Karmali, R.N., et al., The role of substance use disorders in experiencing a repeat opi[INVESTIGATOR_46229], and substance use treatment patterns among patients with a non -fatal opi[INVESTIGATOR_46229].  Drug Alcohol Depend, 2020. 209: p. 107923.  
13. Waye, K.M., et al., Implementing peer recovery services for overdose prevention in Rhode 
Island: An examination of two outreach -based approaches.  Addict Behav, 2019. 89: p. 85 -
91. 
14. Watson, D.P., et al., Replication of an emergency department -based recovery coaching 
intervention and pi[INVESTIGATOR_268560]'s 
Opi[INVESTIGATOR_268561].  J Subst Abuse Treat, 2020. 108: p. 88 -94. 
15. Welch, A.E., et al., Relay: A Peer -Delivered Emergency Department -Based Response to 
Nonfatal Opi[INVESTIGATOR_268562].  Am J Public Health, 2019. 109(10): p. 1392 -1395.  
16. Samuels, E., Emergency department naloxone distribution: a Rhode Island department of 
health, recovery community, and emergency department partnership to reduce opi[INVESTIGATOR_268563].  R I Med J (2013), 2014. 97(10): p. 38 -9. 
17. Samuels, E.A., et al., Adoption and Utilization of an Emergency Department Naloxone 
Distribution and Peer Recovery Coach Consultation Program.  Acad Emerg Med, 2019. 
26(2): p. [ADDRESS_326851] of Patient Navigation With or Without Financial Incentives on 
Viral Suppression Among Hospi[INVESTIGATOR_268564]: A 
Randomized Clinical Trial.  Jama, 2016. 316(2): p. 156 -70. 
19. By[CONTACT_7943], K.A., et al., Inpatient link to peer recovery coaching: Results from a pi[INVESTIGATOR_268565].  Drug Alcohol Depend, 2020. 215: p. 108234.  
20. Williams, A.R., et al., Development of a Cascade of Care for responding to the opi[INVESTIGATOR_174085].  Am J Drug Alcohol Abuse, 2019. 45(1): p. 1 -10. 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326852] Dis, 2012. 
31(1): p. [ADDRESS_326853], J., W. Hall, and R.P. Mattick, Role of maintenance treatment in opi[INVESTIGATOR_2561].  
Lancet, 1999. 353(9148): p. 221 -6. 
23. Bohnert, A.S., et al., A pi[INVESTIGATOR_200772].  Drug Alcohol Depend, 2016. 163: p. 40 -7. 
24. Coffin, P.O., et al., Behavioral intervention to reduce opi[INVESTIGATOR_200782] -risk 
persons with opi[INVESTIGATOR_2427]: A pi[INVESTIGATOR_2269].  PLoS One, 2017. 
12(10): p. e0183354.  
25. Park, T.W., et al., Understanding Risk Factors for Opi[INVESTIGATOR_268566].  J Addict Med, 2016. 10(6): p. 369 -381. 
26. Pouget, E.R., et al., Development of an opi[INVESTIGATOR_2480] -related Overdose Risk Behavior Scale 
(ORBS).  Subst Abus, 2017. 38(3): p. 239 -244. 
27. Cleland, C.M., et al., Between - and within -person associations between opi[INVESTIGATOR_268567], suicidal ideation, pain severity, and pain interference.  Drug Alcohol 
Depend, 2020. 206: p. 107734.  
28. Coffin, P.O., et al., Identifying injection drug users at risk of nonfatal overdose.  Acad 
Emerg Med, 2007. 14(7): p. 616 -23. 
29. Gutiérrez -Cebollada, J., et al., Psychotropic drug consumption and other factors 
associated with heroin overdose.  Drug Alcohol Depend, 1994. 35(2): p. 169 -74. 
30. Cone, E.J., et al., Oxycodone involvement in drug abuse deaths. II. Evidence for toxic 
multiple drug -drug interactions.  J Anal Toxicol, 2004. 28(4): p. 217 -25. 
31. Park, T.W., et al., Benzodiazepi[INVESTIGATOR_268568]: case -cohort study.  Bmj, 2015. 350: p. 
h2698.  
32. Paulozzi, L.J., Prescription drug overdoses: a review.  J Safety Res, 2012. 43(4): p. 283 -
9. 
33. Strang, J., et al., Overdose training and take -home naloxone for opi[INVESTIGATOR_10695]: prospective 
cohort study of impact on knowledge and attitudes and subsequent management of 
overdoses.  Addiction, 2008. 103(10): p. [ADDRESS_326854], and W. White, The Assessment of Recovery Capi[INVESTIGATOR_307]: Properties 
and psychometrics of a measure of addiction recovery strengths.  Drug and Alcohol 
Review, 2013. 32(2): p. 187 -194. 
35. Arain, M., et al., What is a pi[INVESTIGATOR_65219]? A review of current practice and 
editorial policy.  BMC Med Res Methodol, 2010. 10: p. 67.  
36. Olfson, M., et al., Trends in Intentional and Unintentional Opi[INVESTIGATOR_268569], 2000 -2017.  Jama, 2019. 322(23): p. 2340 -2342.  
37. Harris, P.A., et al., Research electronic data capture (REDCap) --a metadata -driven 
methodology and workflow process for providing translational research informatics 
support.  J Biomed Inform, 2009. 42(2): p. 377 -81. 
38. Curran, G.M., et al., Effectiveness -implementation hybrid designs: combining elements of 
clinical effectiveness and implementation research to enhance public health impact.  Med 
Care, 2012. 50(3): p. 217 -26. 
39. Kroenke, K., R.L. Spi[INVESTIGATOR_626], and J.B. Williams, The PHQ -9: validity of a brief depression 
severity measure.  J Gen Intern Med, 2001. 16(9): p. 606 -13. 
40. Sobell, L.C., et al., Reliability of a timeline method: assessing normal drinkers' reports of 
recent drinking and a comparative evaluation across several populations.  Br J Addict, 
1988. 83(4): p. [ADDRESS_326855] J Emerg Med, 2015. 16(3): p. 381 -4. 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326856] for Nicotine Dependence: a revision of the 
Fagerstrom Tolerance Questionnaire.  Br J Addict, 1991. 86(9): p. 1119 -1127.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
76 
 APPENDIX A: DATA AND SAFETY MONITORING PLAN (DSMP)  
BRIEF STUDY OVERVIEW . The primary objective of the CTN -0107 (PI[INVESTIGATOR_8571]) study is to advance 
understanding and improve outcomes for individuals who have experienced a recent non -fatal 
overdose involving opi[INVESTIGATOR_2438] (NFOO). The study will recruit individuals from Emergency Department 
(ED) after surviving a NFOO in the past [ADDRESS_326857] 30 days.  The preliminary effectiveness of a specialized peer recovery 
intervention tailored for overdose survivors, called  Peer Intervention to  Link Overdose survivors 
to Treatment ( PI[INVESTIGATOR_8571]) , will be evaluated as  compared to treatment as usual (TAU) in the ED to 
determine if the PI[INVESTIGATOR_268570].   
The PI[INVESTIGATOR_268571] a prospective, randomized, controlled preliminary trial that will recruit 
approximately [ADDRESS_326858] 30 days. If they are presenting in the ED f or another issue, 
they may still be eligible for the study. Participants will be randomized 1:[ADDRESS_326859] reduced overdose risk compared to those randomized to TAU based on an overdose risk 
behavior scale. Secondarily, the study will assess: 1)  whether NFOO survivors within an ED 
setting are willing to engage with Certified Peer Support Specialists (CPSS) using the PI[INVESTIGATOR_268533], and 2) if participants randomized to PI[INVESTIGATOR_268572] a substance use 
disorder cascade of c are and engagement in treatment.   
1.0 OVERSIGHT OF CLINICAL RESPONSIBILITIES  
A. Site Principal Investigator  
[INVESTIGATOR_9842]’s Principal Investigator ( PI) is responsible for study oversight, including 
ensuring human research subject protection by [CONTACT_9939], trained 
research staff and medical clinicians to assess, report, and monitor adverse events.  
Targeted  Safety Events  occurring during the clinical trial will be collected, documented, and 
reported by [CONTACT_9940] -investigators according to the Protocol.  
Reportable Safety Events should ideally be  entered into the data system within 48 hours  of the 
site staff becoming aware of the event , but no later than within 7 days of site awareness . Death -
related Safety Events are required to be entered into the data system within 24 hours of site's 
knowledge of a confirmed death  event.  
B. CCC Safety Monitor/ Medical Monitor  
The NIDA  CTN Clinical Coordinating Center ’s (CCC) Safety Monitor/ Medical Monitor  or designee  
is responsible for reviewing all Safety Events  reported. The CCC Safety Monitor/ Medical Monitor 
is alerted via email each time a death event  is reported in the EDC  system . All death events  will 
be reviewed at the time they are reported in the EDC  system . Where further information is needed , 
the Safety Monitor/ Medical Monitor or designee will discuss the event with the site  staff. Reviews 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, 2022  
 
CONFIDENTIAL  
77 of Safety Events  by [CONTACT_200893]/ Medical Monitor or designee will be documented in 
the safety database. All Safety Events  are reviewed on a weekly basis to observe trends or 
unusual events.  
Voluntary Regulatory Reporting in non -IND Trials:  
For non -IND trials, if an event meets expedited reporting criteria (serious, related , and 
unexpected) the CCC Safety Monitor/ Medical Monitor or designee will voluntarily report to 
FDA/Regulatory Authorities using the MedWatch Form [ADDRESS_326860] (DSMB)  
The NIDA CTN DSMB affiliated with this trial will be responsible for conducting periodic reviews 
of accumulating safety, trial performance, and outcome data. Reports will be generated and 
presented for Data  and Safety Monitoring Board (DSMB) meetings.  The DSMB will receive listing s 
of Safety Events, to include deaths,  at a frequency requested by [CONTACT_4318], but at least annually.  
Furthermore, the DSMB will be informed of any expedited Safety Event reporting . The DSMB will 
make recommendations to NIDA CCTN as to whether there is sufficient support for continuation 
of the trial, evidence that study procedures should be changed, or evidence that the trial (or a 
specific site) should be halted for reasons relating to safety of the study participants or inadequate 
trial performance (e.g., poor recruitment).  
Following each DSMB meeting, the NIDA CCTN will communicate the outcomes of the meeting, 
based on DSMB recommendations, in writing to the study Lead Investigator. This communication 
summarizing  study safety information will be submitted to participating IRBs.  
D. Quality Assurance (QA) Monitoring  
The monitoring of the study site (s) will be conducted on a regular basis using a combination of 
NIDA  CCTN CCC monitors (if applicable) and the  Local Node QA Monitors (if applicable). 
Investigators will host periodic visits for the monitors . The purpose of these visits is to assess 
compliance with GCP requirements  and other applicable regulatory requirements,  as well as to 
document the integrity of the trial progress.  The investigative site will provide direct  access to all 
trial related sites  (e.g., pharmac y, research office), source data/documentation, and reports for 
the purpose s of monitoring and auditing by [CONTACT_85231], as well as for the inspection by [CONTACT_21229]. Areas of particular concern will be the review of inclusion/ exclusion criteria, 
participant Informed Consent Forms, protocol adherence, safety monitoring, IRB reviews and 
approvals, regulatory documents, participant records, and Principal Investigator [INVESTIGATOR_268573]. The monitors will interact with the site  staff to identify issues and re -train 
the site as needed to enhance research quality.  
Site Visit Reports will be prepared by [CONTACT_200894].  These 
reports will be sent to the site Principal Investigator, the study Lead Investigator and NIDA  CCTN .  
Local Node QA site visit reports  will be prepared following each site visit, as applicable. These 
reports  are sent to those entities required of them by [CONTACT_268655], generally 
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326861] participant identifiers  on-
site, as well as  secure computing procedures for entering and transferring electronic data. The 
documents or logs linking the study codes with the study participant on-site will be kept 
locked /securely stored  separately from the study files and the medical records.  No identifying 
information will be disclosed in report s, publications or presentations.  
Information Meeting Reporting Requirements  
The consent form will specifically state the types of information that are required for report ing and 
that the information will be reported as required. These include suspected or known sexual or 
physical abuse of a child or elders, or threatened violence to self and/or others.  
Participant  Protection  
The site’s study clinician  or other designated and qualified individual  will evaluate all pertinent 
screening and baseline assessments prior to participant randomization to ensure that the 
participant is eligible and safe to enter the study. Safety Events  will be assessed and documented 
at each study  visit. Individuals who experience a Safety Event  that compromises safe participation  
in a study  will be discontinued from further study intervention  and provided referrals for other 
treatment or to specialized care.  Study personnel will request that the participant complete an 
end-of-intervention  visit to assure safety and to document end -of-intervention  outcomes.  
Pregnancy  
As there is no medication intervention, pregnancy  will not be followed within  the context of this 
study .  
Study Specific Risks  
The potential risks associated with study participation are minimal. There is a risk of loss of 
confidentiality of personal information as a result of participation in this study. To mitigate this risk 
and ensure confidentiality, participants will be given  a de-identified study code (participant ID), 
and data and CRFs will be stored in secure databases and kept in locked/securely stored research 
offices. Only designated study staff will have access to research materials.  
There is the potential risk for the interview questions and/or assessments to evoke emotional 
discomfort or distress for participants when they are asked  to recall past situations that were 
unpleasant or distressing (e.g., past overdoses). This is unlikely to be serious in nature, however, 
participants will be given the opportunity to refuse to answer questions.  
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326862] attempts. The PI[INVESTIGATOR_268574] -engagement, when participants/ patients are lost or are 
not engaging in the intervention. The PI[INVESTIGATOR_268575] -engage the participant, 
when necessary. Re -engagement will include multiple attempts and forms of communication to 
the participant as well as reaching out to fa mily and friends to get in touch with the participant 
(their contact [CONTACT_268656]). Some participants may 
experience discomfort or frustration during this re -engagement process. However, participation in 
this stud y is voluntary and participants can withdraw their consent from the study at any time. If 
that occurs, the research team and PI[INVESTIGATOR_268576].  
There is the potential for unknown risks to occur during the study. If any additional risks arise that 
may affect the subject’s decision to participate, the research team will inform the subjects.  
2.0 DATA MANAGEMENT PROCEDURES  
This protocol will utilize a centralized Data and Statistics Center (DSC). A web -based distributed 
data entry model will be implemented. Th ese electronic data capture system s (Advantage  
eClinical  and Qualtrics ) will be developed to ensure that guidelines and regulations surrounding 
the use of computerized systems in clinical trials are upheld.  
3.0 DATA AND STATISTICS CENTER RESPONSIBILITIES  
The DSC will: 1) develop and apply data management procedures to ensure the collection of 
accurate and good -quality data, 2) provide source documents and electronic Case Report Forms 
(eCRFs) for the collection of all data required by [CONTACT_1758], 3) develop data dictionaries for each 
eCRF that will comprehensively define each data element, 4) prepare instructions for the use of 
Advantage  eClinical  and for the completion of eCRFs, 5) conduct ongoing monitoring activities on 
study data collected from all partic ipating sites, and 6) perform data cleaning activities prior to the 
final study database lock.  Data from mobile surveys , which will be managed by [CONTACT_200854] (in 
REDCap ) will be monitored for completeness and quality to the extent possible.  
4.[ADDRESS_326863] entry into the eCRF  in Advantage eClinical, 
or into Qualtrics directly by [CONTACT_268657] . If Advantage  eClinical  is unavailable, the DSC 
will provide the sites with paper source documents and completion instructions. Data will be 
entered into Advantage  eClinical  in accordance with the instructions provided during pro tocol -
specific training and gu idelines established by [CONTACT_9928].  Data entry into the eCRFs is performed 
by [CONTACT_4539]. Selected source documents and eCRFs may also require the 
investigator’s signature  (wet or electronic) . In some situations,  data collected on source 
documents will not be entered into Advantage  eClinical , but when it is entered, it will follow the 
guidelines stated above.   
NIDA CTN -0107  Version 6.0 
Peer Intervention for Overdose – PI[INVESTIGATOR_268394] 26, [ADDRESS_326864] regular monitoring visits, during which, audits 
comparing source documents to the data entered on the eCRF will be performed. Any 
discrepancies identified between the source document and the eCRF will be corrected by [CONTACT_779].  
Trial progress and data status reports, which provide information on items such as recruitment, 
availability of primary outcome, treatment exposure, attendance at long term follow -up visits, 
regulatory status, and data quality, will be generated daily and posted to a secure website. These 
reports are available to the site, the Local Node staff , the lead investigative team , the coordinating 
centers, and NIDA  CCTN , to monitor the sites’ progress on the study.  
6.0 DATA LOCK AND TRANSFER  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at the DSC. Individual participants and their research 
data will be identified by a unique study identification number; further, some identifiable data may 
be collected in eClinical. The study data entry and study management syste ms used by [CONTACT_200895].  
At the conclusion of data collection for the study, the DSC will perform final data cleaning activities 
and will “lock” the study database from further modification. The final analysis dataset will be 
transferred to the Lead Investigator or designee. De -identified versions of these datasets will also 
be provided to the NIDA CCTN -designated part y for storage and archiving. These datasets will 
be posted on the NIDA Data Share website.  
Reference:  http://grants.nih.gov/grants/guide/notice -files/not98 -084.html  